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1. INTRODUCTION 
 
 
 
1.1. Drug abuse, drug addiction and doping 
 
 
Drug abuse is an important global problem with a strong economic, personal and social impact. 
In the “World Drug Report” 2014 the United Nations Office on Drugs and Crime (UNODC) 
estimates that, in 2012, between 162 and 324 million people, that is 3.5% to 7.0% of the population 
aged 15-64, used illicit substances at least once in the previous year and that about half of that 
number used illicit drugs at least once during the month before the assessment
1
. The problem is not 
limited to illicit substances, but concerns also legal psychoactive drugs, such as alcohol, tobacco 
and medications. Recently, there has been an increase in the non-medical use of prescription drugs, 
such as a number of opioid analgesics (used in the treatment of pain), tranquillizers and sedatives 
(employed to treat anxiety and sleep disorders) and prescription stimulants (prescribed for the 
treatment of attention deficit hyperactivity disorder (ADHD)). While in Europe the extent of this 
phenomenon has not been fully evaluated (though some European countries have reported non-
medical use of prescriptions drugs), in the USA the problem has dramatically increased over the last 
years
1,2
. 
Drug abuse can lead to the phenomenon of addiction, defined as a chronic, relapsing brain 
disease characterized by compulsive drug seeking and use, despite harmful consequences
3,4
. 
Addiction arises from the changes in the brain electrical structure that the drugs produce over time. 
Drugs of abuse activate the brain’s reward system, particularly the mesocorticolimbic dopaminergic 
pathway, producing positive reinforcing effects that powerfully compel people to keep using drugs, 
thus leading to addiction
4
. Moreover, long-term abuse causes neurobiological changes that impair 
cognitive function and may trigger mental disorders
3
. Besides effects on the brain, drug abuse has 
other serious health consequences, such as chronic diseases and organ failure associated with 
repeated use, blood-borne bacterial and viral infections (among injecting drug users, 17.9% is HIV 
positive and 50% is infected with HCV) and acute toxic effects, including overdose. Each year 
between 104,000 and 263,000 deaths are related to or associated with the use of illicit drugs and 
over half of these deaths are fatal overdose cases occurring mainly in young people in the mid-
7 
 
 
 
thirties. In addition, drug abuse strongly affects society on multiple levels. For example, illicit drug 
use generates criminal activities, people under the influence of drugs can cause accidents and the 
risk of spreading infectious diseases is increased
1,3
. Different strategies can be employed to reduce 
drug abuse and limit its negative consequences. Prevention programs aimed to increase the 
awareness of drug-induced harms have proved to be effective in decreasing drug abuse
3
; controls 
carried out on people that perform particular tasks, such as those requiring high attention (e.g. 
driving), in order to ascertain drug intake can prevent accidents; proper medical treatment helps 
patients improve their health conditions and the quality of their lives and limits the social harm 
related to drug abuse. 
  
8 
 
 
 
2. AIM OF THE THESIS WORK 
 
The aim of this thesis work was to develop original analytical methods for the determination of 
drugs with a potential for abuse, of substances used in the pharmacological treatment of drug 
addiction in biological samples and of potentially toxic compounds added to street drugs.  
In fact reliable analytical methods can play an important role in this setting. They can be 
employed to reveal drug intake, allowing the identification of drug users and to assess drug blood 
levels, assisting physicians in the management of the treatment. Pharmacological therapy needs to 
be carefully monitored indeed in order to optimize the dose scheduling according to the specific 
needs of the patient and to discourage improper use of the medication. 
In particular, methods have been developed in this thesis work for the detection of gamma-
hydroxybutiric acid (GHB), prescribed for the treatment of alcohol dependence; glucocorticoids, 
one of the most abused pharmaceutical class to enhance sport performance; and adulterants, 
pharmacologically active compounds added to illicit drugs for recreational purposes. All the 
presented methods are based on capillary electrophoresis (CE) and high performance liquid 
chromatography (HPLC) coupled to various kinds of detectors (diode array detector, mass 
spectrometer); biological sample pre- treatment was carried out using different extraction 
techniques, namely liquid-liquid extraction (LLE) and solid phase extraction (SPE). Different kind 
of matrix have been considered: human plasma, dried blood spots, human urine, simulated seized 
powders. The developed analytical methods will be individually described and discussed in the 
following chapters. 
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3. ANALYSIS OF GAMMA-HYDROXYBUTIRIC 
ACID (GHB) IN HUMAN PLASMA BY CE-DAD 
WITH INDIRECT DETECTION 
 
 
3.1. Introduction 
 
Alcohol is one of the most frequently abused drugs and it has an high tendency to cause mental 
disorders and death as a result of chronic use
1,5
. According to a recent study, it appears to be more 
harmful than cannabis, lysergic acid diethylamide and ecstasy
6
. A substantial number of individuals 
are co-dependent on these drugs and this leads to an increased risk of medical complications and 
negative health consequences. Alcohol dependence still represents a significant global problem 
affecting millions of people in the world
5
 and it is responsible for an high demand of treatment, thus 
reflecting the considerable harm associated with alcohol abuse
1,7
. The combination of psychosocial 
support and pharmacological therapy showed to be the most effective approach to alcohol 
dependence
7
. 
-Hydroxybutyric acid (GHB) is naturally occurring in the mammalian brain tissue where it is 
believed to act as a neurotransmitter
8
. It is also found in heart, liver, kidney, muscle and brown fat, 
but its function is still unknown. GHB has been found to be useful in the treatment of narcolepsy
9
 
and of alcohol withdrawal
7
: it reduces craving and prevents withdrawal symptoms relieving the 
patient of the need to use alcohol, it has a low potential for abuse and a low risk of overdose 
fatalities.  
On the other hand body builders have consumed the compound as it stimulates the secretion of 
growth hormone
10
.  
Furthermore, it has recently become a public health issue as a club drug (called liquid ecstasy) 
and appears occasionally in drug-facilitated sexual assaults. This is due to its effects and chemical 
properties as it is colourless and odourless liquid, which can be easily mixed with drinks
11
.  
The principal clinical effect of exogenously administered GHB is Central Nervous System 
depression, effect that may be mediated by a specific GHB receptor, binding to γ-aminobutyric acid 
(GABA) receptors, modulation of GABA levels or interactions with other neurotransmitters. The 
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range between the therapeutic effects and toxic ones is narrow, frequently resulting in headache, 
nausea, vomiting, respiratory depression and coma
12
. 
Consequently, the correct determination of GHB is important in both forensic and clinical 
toxicology. Many previously reported analytical methods detect GHB in different biological 
matrices and involve the use of gas chromatography (GC)
13,14,15,16,17,18,19
, high performance liquid 
chromatography (HPLC)
20,21,22
 with different detector and capillary zone electrophoresis 
(CE)
23,24,25
. 
The qualitative techniques include infrared (IR) spectroscopy
15
, nuclear magnetic resonance 
(NMR) spectroscopy
16
 and colorimetry
17
. 
The outcome of GHB is highly variable depending on different factors, including individual 
metabolism. For this reason, it would be advisable to carefully monitor plasma levels of GHB in 
order to tailor the dose to each patient’s needs. To these purposes, it is desirable to have at disposal 
high-sensitivity, low-cost analytical methods to determine plasma levels of GHB.  
The aim of the present work was to develop a CE-DAD method with indirect detection for the 
determination of GHB in human plasma in order to perform therapeutic drug monitoring in patients 
under treatment for alcohol abuse.  
 
γ-Hydroxybutyric acid (GHB) 
 
 
Hexanoic acid (IS) 
 
 
γ-Aminobutyric acid (GABA) 
 
Figure 1. Chemical structures of GHB and hexanoic acid, used as internal standard (IS), compared to GABA structure.  
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3.2. Experimental 
 
 
Chemicals 
 
GHB (gamma-hydroxybutyric acid) has been provided by LGC Standards Srl (Sesto San 
Giovanni, Milan). 
Hexanoic acid used as internal standard (IS) was provided by Janssen Chimica (Beerse, 
Belgium). 
Methanol, used for dilutions, for the precipitation of the proteins and for the preparation of the 
background electrolyte (BGE), benzoic acid, used for the BGE, were supplied by Sigma Aldrich 
(Steinheim, Germany). 
CTAB (cetyl-trimethylammonium bromide), used for the preparation of BGE, sodium hydrogen 
phosphate, used to prepare the phosphate buffer, and sodium hydroxide, were supplied by Carlo 
Erba (Milan, Italy). 
The ultrapure water (18.2 MΩ cm) was obtained using a Milli-Q system supplied by Millipore 
(Milford, Massachusetts, USA) 
 
 
Preparation of stock and working solutions 
 
The stock solution (1 mg/mL) of GHB was purchased from the pharmaceutical manufacturer. 
The stock solutions (1 mg/mL) of hexanoic acid (SI) were prepared by diluting the solution of 
hexanoic acid with a density of 0.927 g / mL . the exact volume of 10.8 µL of this solution were 
diluted with MeOH in a 10 mL volumetric flask. 
Working solutions were prepared, daily, by diluting stock solutions to desired concentrations, 
with a mixture of phosphate buffer 25 mM, pH 7.4 / MeOH (25:75 v/v). All solutions were stored in 
the freezer at a temperature of -20 ° C. 
The backgound electrolyte (BGE) is constituted by a benzoate buffer 15 mM at pH 5.5 
containing 0.5 mM CTAB and MeOH to 30% (v / v). 
This buffer is prepared as follows: 91.5 mg of benzoic acid is weighted ad dissolved with 
approximately 25 mL of water, agitated on a plate heated to 37 ° C. let the solution col avoiding the 
12 
 
 
 
formation of benzoate cristals. CTAB (9.1 mg) and 15 mL of MeOH are added to the clear solution 
obtained. The solution is adjusted to pH 5.5 with 1 M NaOH, appropriately diluted, and then 
transferred to a 50 cc flask and brought to volume with water. 
 
 
Sample collection 
 
Blood samples (3 mL) were drawn from patients subjected to therapy with GHB at Drug 
Addiction Treatment Centres (Ser.T.) in Bologna (Italy). Blood samples were usually collected in 
the morning from fasting patients, 2-3 hours after the last drug administration. The study was 
approved by local review board and informed consent was obtained for experimentation with 
human subjects. Blood was stored in glass tubes containing ethylenediaminetetraacetic acid 
(EDTA) as the anticoagulant and then centrifuged (within 2 hours from collection) at 4000 rpm for 
15 minutes at 5°C. The supernatant (plasma) was then transferred to polypropylene tubes and stored 
at -80°C until analysis. Blood samples from healthy volunteers, used as blank samples, were treated 
in the same way. 
 
 
Sample pre-treatment 
 
For the analysis of GHB in plasma samples, 100 µL of plasma were added to aliquots of 10 µL 
of GHB and SI (or IS only) taken from the stock solutions. MeOH was then added to this solution to 
obtain a final volume of 400 µL. The solution thus obtained was stirred for 3 minutes and then 
centrifuged (4000 rpm, 5° C, 10 minutes). The supernatant was collected and filtered through a 
cellulose filter  0.20 µm. The final solution was injected into the CE system. 
 
 
Equipment 
 
The instrument used for the analysis of GHB in plasma is a capillary electrophoresis system (CE-
3D, Agilent, Palo Alto - CA, USA) equipped with a photodiode array detector (DAD). 
The separation was conducted using a fused silica capillary (Composite Metal Services, Hallow 
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UK) with the following characteristics: total length (TL) of 48.5 cm, effective length (EL) of 40.0 
cm and internal diameter (ID ) of 50 microns. 
The samples were injected from the anode side of the capillary by means of a pressure of 50 
mbar for 25s. 
The applied voltage was -30 kV. The wavelength of 210 nm was set for detection. 
At the beginning of each day, the capillary was conditioned with ultrapure water, 1N NaOH, 
ultrapure water and BGE, for ten minutes each.  
A Crison (Barcelona, Spain) MicropH 2000 pHmeter, a Hettich (Tuttlingen, Germany) Universal 
32 R centrifuge and an IKA (Staufen, Germany) RV 10 rotary evaporator were also used. 
Data were handled by means of ChemStation software from Agilent (Santa Clara, CA, United 
States). 
 
 
Method validation 
 
The method was validated according to USP XXXVIII 
26
 and “Crystal City”27,28 guidelines. 
 
 
- Linearity, limit of quantitation, limit of detection 
 
Aliquots of 10 µL of analyte standard solutions at six different concentrations, containing the IS 
at a constant concentration, were added to 100 µL of blank plasma. The resulting calibration 
standards were subjected to the previously described pretreatment procedure and then injected into 
the CE system. Calibrators were prepared in triplicate for each point and covered the following 
plasma range: 2.0-320 µg mL
-1
. The concentration of the IS was 20 µg mL
-1
. The analyte/IS peak-
area ratios obtained were plotted against the corresponding concentrations of the analytes 
(expressed as µg mL
-1
) and the calibration curves were constructed by means of the least-square 
method. 
The limit of detection (LOD) and limit of quantitation (LOQ) were calculated as the analyte 
concentrations which give rise to peaks whose heights are 3 and 10 times the baseline noise, 
respectively. 
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- Extraction yield and precision 
 
For these assays plasma samples at three different concentrations of the analytes, corresponding 
to the lowest, the intermediate and the highest point of the calibration curve, were prepared. The 
samples, containing 2.0, 160.0 and 310.0 µg mL
-1
 of GHB and were subjected to the previously 
described pre-treatment procedure and injected into the CE. The analyte peak areas of the spiked 
samples were compared to those obtained injecting standard solutions at the same theoretical 
concentrations and the extraction yield (expressed as percentage value) was calculated. 
The assays described above were repeated six times within the same day to obtain repeatability 
(intraday precision) and six times over six different days to obtain intermediate precision (interday 
precision), both expressed as percentage relative standard deviation values (RSD%). 
 
 
- Selectivity 
 
The selectivity of the method was evaluated with respect to endogenous and exogenous 
compounds. Blank plasma samples from six different healthy volunteers were processed in the 
absence of the IS and the resulting electropherograms were checked for possible interference at the 
retention time of the analytes and the IS. Selectivity towards exogenous substances was investigated 
by injecting into the CE system standard solutions of several compounds that could be co-
administered in clinical practice. A substance was classified as interfering if it gave rise to a peak 
that was not baseline separated from those of the analytes or the IS. 
 
 
- Stability 
 
Stock solution stability was tested by comparing the analyte/IS peak-area ratios of a standard 
solution (containing 10 µg mL
-1
 of GHB) prepared from stock solutions stored for 1 month at -20°C 
with those of a standard solution at the same theoretical concentrations obtained from  fresh stock 
solutions (n = 3). Stability assays were also carried out in blank plasma samples fortified with 10 µg 
mL-1 of GHB. Sample stability was evaluated over five hours at room temperature, after three 
freeze- thaw cycles and after 1 month of storage at -80°C (n = 3 per storage condition).  
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- Analysis of plasma samples from patients in treatment with GHB 
 
For the analysis of GHB in real samples, 10 µL of SI were added to 100 µL of plasma 
samples collected from patients in therapy with Alcover®. The mixtures thus obtained were 
subjected to the procedure of precipitation with MeOH.  The solution is then injected in the CE. 
The values of the ratios of the peak areas electrophoretic analyte / SI were interpolated on the 
calibration curve built on plasma samples to obtain plasma concentrations of the analyte. 
 
 
- Accuracy 
 
Analyte standard solutions at three different concentrations (in order to obtain analyte additions 
of  5.0, 20.0 and 50.0 µg mL
-1
 of GHB) were added to plasma samples collected from patients 
under Alcover® treatment whose analyte concentrations had been previously determined (n = 3 for 
each level); then, the mixtures were subjected to the pretreatment procedure. Accuracy was 
expressed as percentage recovery and was calculated according to the following formula: 100  
([after spiking] – [before spiking]) / [added], where [after spiking] is the sum of the concentrations 
of the analyte in the real plasma and in the analyte standard solution added; [before spiking] is the 
concentration of the analyte in the real sample; and [added] is the concentration of the analyte 
standard solution added to the real sample. 
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3.3. Results and discussion 
 
 
Development of indirect spectrophotometric determination  
 
GHB is a molecule that does not have unsaturation or other chromophores that allow 
direct detection by UV-visible spectrophotometry. To overcome this problem it can be 
derivatized, but this strategy sometimes is not reliable for analytical purposes. 
An indirect spectrophotometric determination of the analyte can be done in CE, using, 
as a component of BGE, an ionic compound with advantageous absorption properties 
called probe. 
 In this case, for the determination of GHB has been used a BGE consisting of benzoic 
acid (Figure 2). Benzoic acid contains a chromophoric group, an aromatic carboxylic acid, 
that shows a an absorption maximum at 210 nm.  
Each time that the analyte, migrating in the capillary, is located in front of the optical 
window, it is observed a negative peak on the absorption line produced by BGE: this peak 
is negative because the analyte considered shows no absorption. 
 
 
 
Figure 2. Chemical structure of benzoic acid 
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BGE optimization  
 
In capillary electrophoresis with indirect spectrophotometric detection the separation 
efficiency and sensitivity of the method is influenced by many factors: the concentration 
of the probe, the running buffer, the pH value, the concentration of the Electroosmotic 
Flow (EOF) modifier. 
A good Background Electrolyte (BGE) for the indirect detection must provide a high 
molar extinction coefficient. The para-hydroxybenzoic acid and benzoic acid, both 
compounds which contain a chromophore group that allows indirect UV detection were 
evaluated as potential probes. It was chosen benzoic acid which allows a better detection 
of the analyte. 
Very important is the mobility of the analytes within the BGE that can be controlled by 
changing the concentration of benzoate or the pH. 
The effect of the concentration of benzoate, on the mobility of analytes, was studied 
using a Cetyl-Trimethyl-Ammonium Bromide (CTAB) concentration of 0.5 mM at pH 5.5, 
in the range between 10 mM and 25 mM. It is observed that the effective mobility of the 
analytes is reduced by increasing the concentration of benzoate, this reduction is due to an 
increase in total ionic strength of the electrolyte. The decrease of the mobility of the 
analytes is accompanied by a parallel increase in the migration time, which improves the 
resolution of GHB, especially in plasma samples of healthy volunteers, increasing the 
migration times of the analyte with respect to the interferences of the plasma. 
However with increasing concentration of benzoate is a decrease of sensitivity in the 
detection, due to the decrease of the ratio of UV absorbance the analyte.  
For this reason, a good compromise, in terms of sensitivity and resolution was obtained 
by choosing a concentration of benzoate equal to 15 mM. 
The electrophoretic mobility of the analytes is pH dependent, because the ionization is 
directly related to the pH of BGE. 
The pH of the BGE was studied in a range from 5 to 6.5, taking into account that the 
pKa of the analyte is ~ 4.5. It was chosen value of 5.5 because it was observed that in 
samples of healthy volunteer this value allowed to have migration times more similar to 
those of the standard solutions. This is probably attributable to an increase of the buffering 
power of BGE at effective pH of 5.5. 
18 
 
 
 
The EOF is considerably reduced, or even eliminated, if the BGE is added a cationic 
surfactant, so it was chosen to achieve this purpose the Cetyl-Trimethyl-Ammonium 
Bromide (CTAB). Tests were carried out also using, as surfactant, the 
Tetrabutylammonium Bromide (TBAB), in a concentration range between 0.25 mM and 
0.5 mM, which, however, has led to a considerable increase of the migration times of the 
analyte, for this reason it was discarded. 
Even the concentration of CTAB in the BGE was studied, in a range between 0.3 and 
0.7 mM, and was observed as an increase in the mobility of the analytes proportional to 
the increase of the concentration of CTAB. However, increasing the concentration of 
CTAB is a reduction of sensitivity because it adds an anion which competes with the ions 
of the solute, while, for concentrations of CTAB less than 0.5 mM is observed a lack of 
reproducibility of migration times. A good compromise between resolution and sensitivity 
was achieved with a concentration of 0.5 mM CTAB.  
The addition of an organic modifier which varies the mobility of the analytes in a 
selective manner can significantly reduce the interference. Since methanol is required by 
pretreatment of biological samples, which occurs through precipitation of the protein, this 
was added to the BGE. 
The percentage of methanol is added has been studied in a range between 10% and 
40%. From the analysis it was evident that the best results, in terms of stability and 
reproducibility of the electrophoretic system, were obtained with 30% methanol.  
The optimal separation was therefore obtained using a BGE with the following 
composition: 
 
- Benzoate buffer 15 mM pH 5.5 
- 0.5 mM CTAB 
- MeOH 30% 
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Internal standard choice  
 
As regards the selection of a suitable internal standard some compounds with no chromophore 
groups, as carboxylic acids, were tested. Among these, the most appropriate was found to be 
hexanoic acid (Figure 1) which, as GHB, does not absorb UV radiation: when it passes in front of the 
optical window it produces a negative peak. Furthermore it showed an electrophoretic behavior similar 
to that of the analyte. In fact his log P is comparable to GHB. 
In this the experimental conditions, the migration time of the internal standard is slightly higher than 
GHB, but still allow short analysis times, less than 4 minutes. The hexanoic acid was used as IS at the 
concentration of 20 g / mL. 
 
 
Optimization of injection conditions 
 
Studies have been performed to optimize the injection conditions to increase the 
sensitivity of the method and avoid a reduction in efficiency. Several tests were carried out 
while maintaining the pressure constant at a value of 50 mbar and gradually increasing the 
injection time from 5 seconds to 35 seconds. There is increased sensitivity of up to 25 
seconds, follow it is observed a peak broadening with consequent loss of efficiency.  
The optimum condition is reached by injecting pressure from the anodic side at 50 mbar 
for 25 seconds. 
 
 
Solvent used for dilution of the analytes 
 
The solvent used to perform dilutions is made from a mixture 75:25 MeOH / 25 mM phosphate 
buffer at pH 7.4. 
This choice has been very important as it has influenced both the height and the efficiency of 
both peaks. 
During an initial screening of solvents to make the dilutions of the standard solutions,  the use 
of methanol was observed to produce a marked increase in sensitivity, compared to the use of 
ultrapure water as shown in Figure 5 and Figure 6. 
Subsequently, performing the tests on healthy volunteers plasma fortified a reduction of 
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reproducibility of the times and areas was observed between the standard solutions and the 
plasma solutions. This phenomenon has been attributed to excessive ionic strength of the 
matrix compared to standard solutions and to the presence of a percentage of organic solvent 
resulting from the pretreatment procedure of the sample. To be able to compare the analysis of 
standard solutions the analysis of plasma samples,  the conditions more similar to those of the 
matrix was reproduced using a 25 mM phosphate buffer pH 7.4 that mimics the characteristics 
of the plasma and the methanol which is used in pretreatment mixture in the same ratio 25:75. 
As can be seen, in the optimized electrophoretic conditions the analytes are well resolved 
within a short total run time and GHB is reasonably separated from EOF( Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Electropherogram of standard water solution containing GHB (20 µg/mL) and hexanoic acid (IS) (20 µg/mL) 
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GHB IS 
IS GHB 
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Figure 4. Electropherogram of standard methanolic solution containing GHB (20 µg/mL) and hexanoic acid (IS) (20 µg/Ml) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Electropherogram of standard solution methanol : water 75:25 containing GHB (20 µg/mL) and hexanoic acid  
 (20 µg/mL) 
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Method Validation 
 
- Calibration curve 
A calibration curve for the standard solutions was built. The concentration range covered was 
between 0.5 and 80 g / mL. The concentration of the IS was 20 µg mL-1.  
The analyte/IS peak-area ratios obtained were plotted against the corresponding concentrations 
of the analytes (expressed as µg mL
-1
) and the calibration curves were constructed by means of the 
least-square method. The equation of the calibration curve is: 
 
y = 0,0592x - 0,002 
 
while the corresponding correlation coefficient is: 
 
R² = 0.9995 
 
demonstrating a good linearity in this concentration range of the calibration curve is shown in 
Figure 6. 
The limit of detection (LOD) and the limit of quantitation (LOQ) were found to be, respectively: 
LOD = 0.15 µg / mL LOQ = 0.5 µg / mL 
 
 
 
 
5 
 
 
4 
 
 
3 
 
 
2 
 
 
1 
 
 
 
0 20 40 60 80 100 
GHB concentration (µg/mL) 
 
Figure 6. Calibration curve of GHB on standard solutions  
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- Repeatability and intermediate precision 
 
The repeatability of the method was verified by running tests on standard solutions of GHB at 3 
different concentrations in the same day. The concentrations of GHB analyzed were 0.5, 40 and 80 
µg / mL, while the concentration of the SI is always remained constant at 20 µg / mL. 
The data relating to the precision of the analysis results are good: the repeatability, expressed as  
intraday RSD% (relative standard deviation percentage) was found to be between 0.45% and 1.32% 
(Table 1). Even the intermediate precision, calculated as RSD% interday, was found to be good, 
with values between 0.71% and 1.91% (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Repeatability in standard solutions 
  
 
 
GHB 
0,5 μg/mL 
 
GHB 
40 μg/mL 
 
GHB 
80 μg/mL 
 
 
Area GHB / Area IS 
 
 
Area GHB / Area IS 
 
 
Area GHB / Area IS 
 
1 
 
0,0218 
 
2,090 
 
4,154 
 
2 
 
0,0213 
 
2,070 
 
4,106 
 
3 
 
0,0221 
 
2,052 
 
4,124 
 
4 
 
0,0220 
 
2,076 
 
4,116 
 
5 
 
0,0216 
 
2,109 
 
4,148 
 
6 
 
0,0217 
 
2,082 
 
4,122 
 
RSD% 
 
1,32% 
 
0,92% 
 
0,45% 
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Table 2. Intermediate precision in standard solutions 
  
 
 
GHB 
0,5 μg/mL 
 
GHB 
40 μg/mL 
 
GHB 
80 μg/mL 
 
 
Area GHB / Area IS 
 
 
Area GHB / Area IS 
 
 
Area GHB / Area IS 
 
1 
 
0,0224 
 
2,038 
 
4,152 
 
2 
 
0,0216 
 
2,088 
 
4,090 
 
3 
 
0,0221 
 
2,118 
 
4,116 
 
4 
 
0,0225 
 
2,076 
 
4,126 
 
5 
 
0,0215 
 
2,098 
 
4,068 
 
6 
 
0,0222 
 
2,086 
 
4,108 
 
RSD% 
 
1,91% 
 
1,28% 
 
0,71% 
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- Development of pretreatment procedure 
 
The analysis of pharmacologically active compounds present in a biological matrix involves a 
preliminary treatment of the clean-up of the biological sample that may be made by various 
techniques: liquid-liquid extraction, protein precipitation (with organic solvents, with suitable saline 
solutions or with acids), procedures for solid phase extraction (SPE) or micro extraction (SPME, 
MEPS). 
For the extraction of GHB from biological samples of plasma various pre-treatment procedures 
were tried including various SPE methods. 
Considering the chemical and physical characteristics of GHB cartridges with different 
characteristics have been tested: 
• SAX, strong anion exchange cartridges, and MAX cartridge mixed mode: d hydrophilic / lipophilic 
balance and anion exchange. Both were discarded due to the incompatibility of the eluent used with 
electrophoresis system. 
•  C8: do not recover the IS and the recovery of GHB is less than 70%. 
•  HLB cartridges hydrophilic / lipophilic balance, discarded because it restrains the GHB. 
In light of the tests performed has abandoned the way of treatment by SPE for the clean-up of 
biological samples. 
The precipitation by addition of organic solvents was performed using acetonitrile and methanol. 
The electropherograms obtained, Figure 8 and Figure 9, using acetonitrile as the precipitating agent, 
there is a yield lower than the extraction of methanol and also a minor purification. 
The methanol was chosen as the precipitating agent and experiments have been made by adding 
to 100 µL of plasma, different volumes of methanol (from 200 µL to 600 µL). The best results in 
terms of yield of extraction were obtained by adding 300 µL of methanol, and then this volume was 
used to precipitate the plasma proteins. 
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GHB IS 
 
Figure 7 Electropherogram of fortified plasma sample spiked with GHB (20 µg/mL) and hexanoic acid (20 µg/mL) after 
acetonitrile protein precipitation pretreatment 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Electropherogram of fortified plasma sample spiked with GHB (20 µg/mL) and hexanoic acid (20 µg/mL) after methanol 
protein precipitation pretretment (zoom of the peak area of interest)  
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- CE analysis of GHB in fortified plasma 
After the setup of pretreatment procedure, the method has been applied to plasma samples. The 
electropherogram of a blank plasma sample collected from an healthy volunteer, after methanolic 
protein precipitation, is showed in Figure 9. It can be observed that the extraction procedure is able 
to remove the interferences from the matrix.  
The electropherogram of a plasma fortified with 80 g / mL GHB (plasma concentration), 
corresponding to 20 g/mL(effective concentration), and 20 g / mL of IS is shown In Figure 10. 
The discrepancy between the concentration in plasma and the concentration  in the injected solution 
is due to the 1:4 dilution of the sample introduced by the process of precipitation of the proteins.  
The two peaks have good symmetry, they appear to be well separated and they have the same 
migration times observed in the analysis of standard solutions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Electropherogram of blank plasma after sample pretreatment procedure 
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Figure 10. Electropherogram of plasma fortified with 80 µg/mL di GHB e 80 µg/mL di SI (plasmatic concentrations) 
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-  Calibration curve 
 
Calibration curve was set up for the analyte in fortified plasma and good linearity (r
2 
> 
0.9993) was found over the concentration range from 2 to 320 µg / mL plasma concentration, 
(corresponding to 0.5 to 80 µg / mL in the injected solution).  
The equation of the curve obtained by the method of least squares is found to be: 
 
y = 0,0127x - 0,227 
 
while the regression coefficient is: 
 
R² = 0.9993 
 
demonstrating a good linearity in this concentration range of the calibration curve shown in Figure 
11. 
The limit of detection (LOD) and the limit of quantitation (LOQ) were respectively: 
LOD = 0.6 g / mL; LOQ = 2 g / mL showing a good sensitivity of the method. 
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Figure 11. Linearity in fortified plasma 
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Analyte 
 
 
Concentration 
(μg/mL)a 
 
Extraction 
yeld (%) 
 
 
Repetability 
(RSD %) 
 
Interday 
Precision 
(RSD %) 
GHB 
 
2 
 
88,03 
 
2,36 
 
4,91 
160 89,30 1,61 2,13 
320 90,90 1,08 1,49 
 
 
- Extraction yield and precision  
 
The tests of repeatability, or intraday precision, and intermediate precision, or interday precision, 
have been performed on fortified plasma samples subjected to protein precipitation procedure with 
methanol. Both are expressed as percentage relative standard deviation values (RSD%) 
Extraction yield and precision assays were carried out at three different concentrations, 
corresponding to the lowest, the intermediate and the highest point of each calibration curve. Three 
different concentrations of GHB: 2, 160 and 320 µg / mL were added to 100 µL of blank plasma, 
while the IS added is maintained at a constant concentration of 20 µg / mL. 
The results of these assays are reported in Table 3. As can be seen, good extraction yield was 
obtained with values higher than 88%; the mean extraction yield of the IS was 95%. Precision was 
also satisfactory, with RSD values always lower than 4.9%.  
The repeatability, expressed as RSD% intraday was found to be less than 2.36% (Table 4). Even 
the intermediate precision, calculated as RSD% interday, was found to be very good with values 
less than 4.91% (Table 5). 
 
 
 
a = plasmatic concentration 
Table 3. Main validation parameters on plasma 
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Table 4.intraday precision in fortified plasma. 
 
Table 5.Interday precision in fortified plasma  
 
GHB 
2 μg/mL 
GHB 
160 μg/mL 
GHB 
320 μg/mL 
Area GHB / Area IS Area GHB / Area IS Area GHB / Area IS 
 
1 
 
0,0204 
 
1,996 
 
4,022 
 
2 
 
0208 
 
1,976 
 
3,996 
 
3 
 
0,0200 
 
1,936 
 
4,090 
 
4 
 
0,0214 
 
1,916 
 
4,114 
 
5 
 
0,0203 
 
1,974 
 
4,068 
 
6 
 
0,0205 
 
1,990 
 
4,042 
 
RSD% 
 
2,36% 
 
1,61% 
 
1,08% 
 
GHB 
2 μg/mL 
GHB 
160 μg/mL 
GHB 
320 μg/mL 
Area GHB / Area IS Area GHB / Area IS Area GHB / Area IS 
 
1 
 
0,0206 
 
1,912 
 
4,146 
 
2 
 
0,0197 
 
1,990 
 
4,134 
 
3 
 
0,0208 
 
1,968 
 
4,050 
 
4 
 
0,0214 
 
2,024 
 
4,236 
 
5 
 
0,0193 
 
1,926 
 
4,114 
 
6 
 
0,0220 
 
1,984 
 
4,172 
 
RSD% 
 
4,91% 
 
2,13% 
 
1,49% 
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- Selectivity 
 
The analysis of plasma samples from six different healthy volunteers showed no evidence of 
unacceptable interference from endogenous compounds at the retention time of the analytes and the 
IS. Several compounds that could be co-administered with GHB during clinical practice, such as 
antipsychotics, antidepressants, nonsteroidal anti-inflammatory and sedative-hypnotics, were tested 
for possible interference; none of them gave rise to peaks that could interfere with the determination 
of the analytes. including, all reported in Table 6. 
Most of the substances have not been revealed in a normal electrophoretic run; other have 
different migration times with respect to the analyte, thus not interfere with the indirect revelation 
of GBH by CE- DAD, ensuring a high selectivity of the method. 
 
 
 
 
ANALYTE Migration time (min) ANALYTE Migration time (min) 
GHB 2,64 HEXANOIC ACID 
(SI) 
2,83 
VALPROIC ACID 3,11 ISOBUTYRIC ACID 2,07 
TOPIRAMATE n.d. GABAPENTIN n.d. 
SALICILIC ACID 4,17 (positive peak) ACETILSALICILIC ACID 4,5 (positive peak) 
INDOMETACIN n.d. QUETIAPINE n.d. 
GABA n.d. VENLAFAXINE n.d. 
LEVOMEPROMAZINE n.d. CARBAMAZEPINE n.d. 
 
Table 6. Selectivity 
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- Stability 
 
The mean difference in the analyte/IS peak-area ratios between a standard solution of the 
analytes prepared from stored stock solutions and a standard solution at the same nominal 
concentration obtained from fresh stock solutions was -0.1%, indicating that all the analytes were 
stable in methanol when stored at -20°C for 1 month. 
Stability was also assessed in plasma samples fortified with known amount of the analytes and 
stored under various conditions. The concentrations of the analytes found after storage were 
compared to the respective theoretical concentrations. The mean differences observed were -0.5% 
for plasma sample kept at room temperature for 6 hours, -1.1% for samples subjected to three 
freeze-thaw cycles and -1.3% for samples stored at -80°C for 1 month. The loss of the analytes was 
not significant, indicating that the compounds are stable under the tested storage conditions. 
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Analysis of plasma samples from patients. Analysis of GHB in the plasma of patients under 
treatment with Alcover® 
 
The validated method was then applied to the analysis of plasma specimens collected from  
patients treated with Alcover®. A 2 L aliquot of IS were added to a volume of 100 L of plasma 
sample. This mixture was subjected to the pretreatment procedure than injected. The 
electropherogram shown in Figure 12 is an example of a plasma sample from a patient treated with 
50 mL / day of Alcover® corresponding to 8.75 g / day. The usual dosage for alcohol withdrawal is 
50 mg/kg/die, for 3 times in a day corresponding to 10.5 g/day for a 70 kg adult male and could be 
augmented till 21g /die after 60 days of treatment.
29
 
 The value of the concentration of GHB obtained by interpolation on the plasma calibration 
curve is 35 µg /mL. The blood sampling was carried out 35 minutes after administration of the drug. 
The maximum plasma concentration is observed, in fact, after 30 minutes of administration.  This 
low plasma value found, which is below the therapeutic range that can vary between 50 µg / mL 
and 120 µg / mL
30
, is consistent to clinical responses registered by the medical staff. In fact the 
patient was considered “non- responder” to the therapy.  
A notable interindividual variability was found among the analysed patients in the plasmatic 
concentrations of GHB (Fig. 13). In some case plasma levels were below therapeutic range. These 
results support the importance of an appropriate monitoring to optimize administration, especially 
during the beginning of the therapy. It’s clear that these analytical data could be powerful tools 
supporting physicians in the pharmacological management of alcohol withdrawal. 
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Figure 12. Electropherogram of a plasma sample from a patient treated with 50 mL/day of Alcover® (8.75 g / day) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Plasma levels of GHB found in patients under Alcover® treatment plotted against the daily administered dose.  
GHB 
IS 
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Accuracy 
 
Method accuracy was evaluated by means of recovery assays. Standard solutions of the 
analytes at three different concentrations were added to plasma  samples from patients under 
GHB treatment (n = 3 for each level) previously analysed and the percentage recovery was 
calculated. Results were satisfactory, as recovery values were always higher than 88.0%. 
 
 
 
 
 
 
 
 
 
 
 
Table 7. Accuracy expressed as recovery % 
  
Analyt
e 
Added concentration 
(μg/mL)a 
Recovery 
(%) 
GHB 
20 88,76 
80 92,97 
200 93,84 
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3.4. Conclusions 
 
An analytical method based on the use of a CE-DAD system, with indirect revelation has been 
developed for the analysis of GHB in plasma of alcoholic patients in therapy with Alcover®.A 
simple technique has been used to perform the clean-up of the matrix, based on the precipitation of 
the protein that allows to obtain high extraction yields (> 88%). Good results in terms of precision 
(RSD% always less than 4.91%) and accuracy (recoveries always above 89.0%). were obtained. 
The indirect revelation method gives a remarkable selectivity. Moreover the use of this 
electrophoretic technique implicates some other advantages as a limited use of organic solvents and 
very short time of analysis, always less than 5 minutes. 
One of the novelties of this work is represented by the analysis of GHB based on an indirect 
DAD detection, taking advantage of GHB physical and chemical properties. When compared to 
other methods reported in the literature which make use of mass spectrometry [17,18,20-23,25,27-
34,36], CE with indirect DAD detection represents a good alternative, as it offers  satisfactory 
sensitivity and high selectivity, it requires less maintenance and it is less expensive. Moreover, it is 
less prone to suffer from matrix effect, which could be a drawback in mass spectrometry detection.  
In conclusion the present work describes an innovative method that has proven to be accurate, 
fast and therefore suitable for therapeutic monitoring of alcoholic patients in therapy with 
Alcover®. 
 
 
Acknowledgments 
 
We would like to thank Dr. Maria Chiara Pieri (Ser.T. East, AUSL Bologna) for providing the 
blood samples of patients receiving Alcover®. 
  
38 
 
 
 
4. DETERMINATION OF GHB IN DRIED BLOOD 
SPOTS FOR THERAPEUTIC DRUG MONITORING 
 
 
 
4.1. Introduction 
 
 
 
The purpose of the present work was the development of a rapid analytical method for the 
analysis of GHB in innovative biological matrix, dried blood spots (DBSs). The technique is 
based on capillary zone electrophoresis with indirect UV absorption detection at 210 nm.  
One of the main difficulties physicians have to face in the management of GHB treatment  
is represented by an heterogeneous response pattern which is partly due to GHB large 
interindividual pharmacokinetic variability
31
. In fact, different studies have evidenced that 
GHB plasma levels vary for a given dose, so contributing to variability in clinical response 
In addition, during therapy, many patients take concomitant medications that might induce 
or inhibit some of the CYP isoforms involved in GHB metabolism, thus affecting its 
pharmacokinetics. This accentuates interindividual response variability and consequentially 
influences the clinical effects and the safety profile of the drug.  
The measurement of hematic concentrations of GHB can help assess patient 
compliance, tailor the dose to the patient’s needs, minimize the risk of dose-related toxicity 
and can be useful for clinical decision making. Thus, an accurate therapeutic drug monitoring 
(TDM) of GHB should be carried out. 
As blood (plasma, serum or whole blood) is the optimal matrix for TDM, the use of dried 
blood spot (DBS) sampling technique can be an attractive approach. In fact, DBSs are easily 
obtained by a finger prick. The resulting drops of blood are collected onto filter paper and 
allowed to dry. The use of DBSs offers several advantages: it avoids venous blood withdrawal, 
thus reducing patient worry, it simplifies storage and transport as no refrigeration is required and 
it decreases the risk of infection with blood-borne pathogens
32
 . 
To the best of knowledge, no analytical method is currently available for the determination of 
GHB in DBSs by means of capillary electrophoresis from patients under alcohol withdrawal 
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treatment. In fact, papers from the literature deal with the determination of GHB in human 
plasma/serum
33
, urine, whole blood
34
 samples by means of HPLC methods with fluorecence 
detection
35
,  Raman spectroscopy
36
 or GC coupled with mass spectrometry (MS)
37
.The proposed 
method is faster and simpler than the others present in literature, and did not require 
derivatisation step. 
Therefore, given the importance of TDM for GHB and the advantages offered by DBS 
sampling technique, the aim of the present study was to optimize the method previously 
developed for the indirect determination of the GHB in human plasma (see page 4) for his 
analysis in DBS. 
 
 
Chemicals 
 
Methanolic stock solution of GHB (1 mg mL
-1
) was purchased from LGC Standards 
(Teddington, UK). Hexanoic acid, used as the internal standard (IS, Figure 1), was from 
Janssen Chemicals (Beerse, Belgium). Acetone and methanol, 85 % (w/w) phosphoric acid 
and disodium hydrogen phosphate were obtained from Sigma Aldrich.  
TRIS (Tris(hydroxymethyl)aminomethane), TBAB Tetrabutylammonium Bromide, 
isovanillic acid, didhydroxybenzoic acid, acetilsalicilic acid, phthalic acid were provided 
by Sigma Aldrich (Steinheim, Germania);  
CTAB (Cetyl-Trimethylammonium Bromide), used for the preparation of BGE, and sodium 
hydroxide, were supplied by Carlo Erba (Milan, Italy). 
Ultrapure water (18.2 MΩ cm) was obtained by means of a MilliQ apparatus by Millipore 
(Milford, MA, USA). 
 
 
Preparation of stock and working solutions 
 
The stock solution (1 mg/mL) of GHB was purchased from the pharmaceutical 
manufacturer. The stock solutions (1 mg/mL) of hexanoic acid (SI) were prepared by diluting 
the solution of hexanoic acid with a density of 0.927 g / mL. The exact volume of 10.8 µL of 
this solution were diluted with MeOH in a 10 mL volumetric flask. 
Working standard solutions were prepared, daily, by diluting primary stock solutions to 
desired concentrations, in ultrapure water. All solutions were stored in the freezer at a 
temperature of  -20 ° C. Stock solutions were stable for at least 3 months when stored at         -
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20°C (as assessed by CE assays). 
 
 
Sample collection 
 
DBS samples were obtained by puncturing the subjects (healthy volunteers and patients 
under GHB) on a finger with single use lancing device. The first drop of blood was wiped away 
using dry sterile gauze, then the blood drops were collected on a FTA
® 
card Whatman® 
International Ltd (Maidstone, Kent, UK ), paying attention not to go outside the pre-marked 
circles. The blood spots thus obtained were left to dry for 3 h in the dark at room 
temperature and then stored in a sealed paper bag (if necessary with a suitable desiccant, i.e. 
silica gel). 
All the blood samples were collected between 8.00 a.m. and 10.00 a.m. from fasting patients 
under GHB at local Drug Addiction Treatment Centres (Ser.T.); this use for TDM was already 
authorised at the time of sampling. 
 
 
Equipment 
 
The instrument used for the analysis of GHB in plasma is a capillary electrophoresis system (CE-
3D, Agilent, Palo Alto - CA, USA) equipped with a photodiode array detector (DAD). 
The separation was conducted using a fused silica capillary (Composite Metal Services, Hallow 
UK) with the following characteristics: total length (TL) of 48.5 cm, effective length (EL) of 40.0 
cm and internal diameter (ID ) of 75 microns. 
The samples were injected from the anode side of the capillary by means of a pressure of 50 
mbar for 10s. 
The applied voltage was -30 kV. The wavelength of 210 nm was set for detection. 
At the beginning of each day, the capillary was conditioned with ultrapure water, 1N NaOH, 
ultrapure water and BGE, for ten minutes each. 
A Crison (Barcelona, Spain) MicropH 2000 pHmeter, a Hettich (Tuttlingen, Germany) 
Universal 32 R centrifuge, an IKA (Staufen, Germany) RV 10 rotary evaporator and a 
microwave  oven  were also  used.  Whatman  (Maidstone,  UK)  FTA
®   
classic  cards 
 
(WB120205) were used for DBS sample collection. 
 
Data were handled by means of ChemStation software from Agilent (Santa Clara, CA, United 
States). 
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BGE preparation 
 
Prior to use, the mobile phase was filtered through Varian nylon filters (47 mm diameter, 
0.2 µm pore size) and degassed by sonication. 
The backgound electrolyte (BGE) is constituted by a TRIS buffer 50 mM and benzoate buffer 
7mM obtaining  pH 8.9. 
This buffer is prepared as follows: 50.4 mg of benzoic acid is weighted ad dissolved with 
approximately 25 mL of water, agitated on a plate heated to 37 ° C. The solution is  cold avoiding 
the formation of benzoate cristals and 302,8 mg of TRIS are added to the clear solution obtained. 
The solution is adjusted to pH 8.9 with 1 M NaOH, appropriately diluted, and then transferred to 
a 50 cc flask and filled with ultrapure water. Prior to use, the BGE was filtered through Varian 
cellulose filters (47 mm diameter, 0.45 µm pore size) and degassed by sonication. 
 
 
Figure 14.TRIS molecular structure 
 
 
 
Extraction from DBS and sample pre-treatment 
 
One or more DBS disks were cut out of the card after the addition of 10 µL of IS 
solution (on CE concentration 10 µg mL
-1
) and were placed into a vial with 300 µL of 
methanol. The vial was put in a votex for 60 s, then it was sonicated for 5 minutes and finally  
centrifuged for 10 min at 4000 rpm. Then the extract was brought to dryness under vacuum 
using a rotary evaporator, dissolved again with 50 µL of methanol and directly injected to 
CE. 
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The volume of blood contained in the blood spot disks was determined by pipetting known 
volumes of blood (from 5 to 50 µL) onto the FTA
®
 paper cards with a micropipette: the diameter 
of the regular-shaped blood spots was then measured and a calibration curve constructed. A 
power equation was fitted and the equation was used to determine the volume of blood 
contained in the DBS disks from patients: 
 
y = 0.931 x
0.352
 
 
where y and x were the diameter and the volume of blood spot, respectively. The 
volume of blood determined in this way was used for calculating the concentration of GHB 
in all samples analysed. 
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Method validation 
 
The method was validated following USP XXXVIII
26
 and “Crystal City”27 
guidelines. 
 
 
- Linearity, limit of quantitation, limit of detection 
 
Aliquots of 6,25 µL of GHB standard solutions at six different concentrations (in order to 
obtain on-capillary concentrations over the 1-200 µg mL
-1 
range), containing the IS at a 
constant concentration (in order to obtain on-capillary concentration of 25 µg mL
-1
), were 
added to DBS disks (after the addition DBS samples were left to dry for at least 1 h). The 
resulting fortified DBS were subjected to the previously described sample preparation and 
injected into the CE system. This procedure was done in triplicate for each point. The 
analyte/IS peak-area ratios were plotted against the corresponding concentrations of the 
analyte (expressed as ng  mL
-1
) and the calibration  curve  was constructed  by means of 
the  least-square method. 
The limit of detection (LOD) and limit of quantitation (LOQ) were calculated as the 
analyte concentrations which give rise to peaks whose heights are 3 and 10 times the 
baseline noise, respectively. 
 
 
- Extraction yield and precision 
 
Aliquots of 6,25 µL of GHB standard solutions at three different concentrations (in order to 
obtain on-capillary concentrations of 4, 50 and 100 µg mL-1), containing the IS at a constant 
concentration (in order to obtain on-capillary concentration of 25 µg mL
-1
) were added to DBS 
disks. The resulting spiked DBS were subjected to the previously described pre-treatment 
procedures and finally injected into the CE system. The analyte peak areas were compared 
to those obtained injecting standard solutions at the same theoretical concentrations and 
the absolute recovery was calculated. 
The assays described above were repeated six times within the same day to obtain 
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repeatability (intraday precision) and six times over six different days to obtain 
intermediate precision (interday precision), both expressed as percentage relative standard 
deviation values (RSD%). 
 
 
- Selectivity 
 
Blank DBS samples from six different healthy volunteers were subjected to the sample 
pre-treatment procedure and injected into the CE system. The resulting chromatograms were 
checked for possible interference from endogenous compounds. The acceptance criterion 
was no interfering peak higher than an analyte peak corresponding to its LOD. 
Furthermore, standard solutions of several different compounds that could be co-
administered in clinical practice were injected into the CE system. A substance was 
classified as interfering if it gave rise to a peak that was not baseline separated from those of 
the analytes or the IS. 
 
 
- Stability 
 
Stability assays were carried out in DBS samples from three patients stored at room 
temperature (25 ± 3°C) over a period of 1 month (n = 3). DBSs were kept in the dark and 
in paper bags with a suitable desiccant (i.e. silica gel). The concentrations of GHB found in 
the stored DBSs were compared to those obtained from the corresponding samples 
extracted and analysed immediately after initial spotting and drying. 
 
 
- Accuracy 
 
Accuracy was evaluated by means of recovery assays. Aliquots of 6,25 µL of GHB standard 
solutions at three different concentrations (i.e. 10, 50 and 100 µg mL
-1
 of GHB on-capillary 
concentrations) containing the IS at a constant concentration (in order to obtain on-capillary 
concentration of 25 µg mL
-1
) were added to real DBS or plasma samples from subjects under 
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Alcover® therapy whose content of GHB was previously determined. 
Recovery values were calculated according to the following formula: 100 ([after spiking] – [before 
spiking]) / [added]. 
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4.2. Results and discussion 
 
 
Development of electrophoretic conditions 
 
Initially, the same electrophoretic conditions used for the analysis of GHB in human plasma 
(i.e.  small inner diameter capillary, 50 µm,  combined with a mixture of benzoic acid CTAB and 
methanol  as  BGE) were applied (see page 10). However, for cheapness and simplicity the 
previous capillary was replaced by another one with grater inner diameter the same functional 
group but with a conventional inner diameter (4.6 mm instead of 3.0 mm). Consequently, the 
mobile phase was adapted to suit the chromatographic behaviour of the analyte and the IS on the 
new column: a mixture of phosphate buffer (25 mM, pH 6.4) and acetonitrile (45:55, v/v) gave 
satisfactory results. 
Some trials were carried out to improve the performance of the CE system in terms of 
selectivity and sensitivity.  
The electropherogram of a standard solution containing 50 µg mL
-1
 of MTD and 25 µg mL
-1
 
of IS is shown in figure. Migration times (mr) are: GHB, tm = 3.0 min; IS, tm = 5.6 min. 
 
 
 
Figure 15 electropherogram of a standard solution containing 50 µg mL-1 of MTD and 25 µg mL-1 Migration times (mr) are: GHB, tm = 3.0 min; IS, 
tm = 5.6 min 
  
47 
 
 
 
Development of the extraction from DBS 
 
Several assays were carried out to obtain reliable results and to optimize extraction efficiency 
of molecules from DBSs. It may vary depending on the best combination of some operating 
parameters, such as the duration of the extraction procedure, the nature of the solvent employed 
and the technique used to aid the removal of the compounds from the filter paper. 
Spiked DBSs were treated with different solvents or mixtures (acidic or basic buffers, 
methanol, acetonitrile, buffer/organic solvent mixtures): aprotic organic solvents proved to be 
unsuitable to remove GHB from the paper (extraction yields < 70%), while aqueous buffers 
eluted red blood cells which interfered with the assay.  Only methanol gave promising results in 
terms of sample cleaning and extraction yields (> 90 %).  
Extraction time and mixing technique were also tested. In particular, ultrasound and vortex 
agitation were investigated. The extraction efficiency for vortex and ultrasound agitation 
increased while increasing the duration of the extraction time from 1 to 5 minutes giving 
satisfactory extraction yield, hence, the combination of these techniques was adopted.  
The methanol was then chosen as the precipitating agent; different volumes of methanol, from 
200 µL to 600 μL were added to a dried blood spot of 25 µL (finely cut to increase the surface 
area). The best results in terms of yield of extraction were obtained by adding 300 µL of 
methanol, and then this volume was used to extract the analyte in solution and at the same time, 
precipitate the proteins. 
The subsequent centrifugation step (4000 rpm for 10 min) allowed to separate the solid residue 
consisting of fragments of paper and denatured proteins by metabolic solution containing the 
analyte. 
The use of pure methanol allowed to dry out the solution obtained by rotary evaporation and 
concentrate the analyte six times (from 300 µL to 50 µL). 
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Method Validation 
 
Calibration curves were set up in blank matrices fortified with different concentrations of 
GHB and a constant concentration of the IS. Good linearity was found in the 1-200 µg mL
-1
  on-
capillary  concentration range . The LOD and LOQ values were 0.3 µg mL
-1
 and 1 µg mL
-1
, 
respectively. 
 
Extraction yield and precision assays were carried out at three different concentration levels of 
GHB, corresponding to the lowest, the intermediate and the highest point of the calibration curve  
The results were satisfactory, being the extraction yield values higher than 90%; the mean 
extraction yield of the IS was 92%. Precision was also good, with RSD values always lower than 
4.6%. 
Table 8 validation parameters 
  
 
 
 
Analita 
 
 
Concentration 
(μg/mL)a 
 
extraction 
yeld (%) 
 
 
Repeatabilit
y 
(RSD %) 
 
intraday 
precision 
(RSD %) 
GHB 
 
1 
 
90,10 
 
2,41 
 
4,62 
50 92,30 1,78 2,17 
200 93,90 1,17 1,27 
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- Selectivity 
 
The analysis of blank DBS and plasma samples from six healthy volunteers showed no 
evidence of unacceptable interference from endogenous compounds at the retention times of 
MTD and the IS. Standard solutions of some opioids and some antipsychotic, antidepressant and 
sedative-hypnotic drugs were injected into the CE system at concentrations higher than the upper 
limit of the calibration curve. None of them gave rise to peaks that could interfere with the 
determination of GHB. 
 
 
- Stability 
 
Stability was evaluated in DBS samples from 3 patients stored for 1 month at room 
temperature. The concentrations of GHB found in the specimens after storage were compared 
with those determined in the fresh samples, revealing a mean difference of -2.3%. This 
percentage of loss is not significant, especially if the relative long time of storage (1 month) is 
considered. Thus, GHB can be considered stable in DBS under the tested condition of storage. 
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SI 
GHB 
Analysis of samples from patients 
 
The method was applied to the analysis of DBS and plasma samples collected from 6 former 
alcohol addicted subjects under Alcover. As an example, the electropherogram of a DBS sample 
from one of these patients treated with 50 mg day-1 of GHB is reported in figure 16 , , a good 
correlation (r
2
 = 0.998) was obtained between the concentrations of GHB found in DBS and those 
found in the corresponding plasma samples, taking into account the presence of haematocrit in 
DBS and its absence in plasma. In fact, since the haematocrit is normally about 40–54% for men 
and 36-46% for women (mean 45%), the concentrations found in DBS samples were multiplied 
by a correction factor of 1.79 to obtain the corresponding plasma concentrations.  
 
 
Figure 16 electropherogram of a DBS sample from one of these patients treated with 50 mg day-1 of GHB 
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Analita 
 
 
Concentration added 
(μg/mL)a 
 
 
Recovery 
(%) 
 1 90,16 
5 90,66 
50 92,84 
 
 
Accuracy 
 
Method accuracy was evaluated by means of recovery assays. Standard solutions of the 
analytes at three different concentrations were added to DBS or plasma samples from patients 
previously analysed and the percentage recovery was calculated. Accuracy was satisfactory, 
being recovery values always higher than 90.0%. 
 
 
 
 
 
 
 
 
 
Table 9  Accuracy 
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4.3. Conclusions 
 
 
 
A reliable CE method with indirect DAD detection has been optimized for the determination 
of GHB in DBS and human plasma samples. GHB removal from DBSs was performed by means 
of ultrasound-assisted extraction, clean up and precipitation with methanol.. The reliability of 
DBS specimens in the determination of GHB blood levels was evaluated: the analyte proved to be 
stable in the DBS matrix for at least one month and the concentrations of GHB obtained from the 
analysis of DBS samples were perfectly comparable with those found in the corresponding 
plasma specimens. No interferences were found neither from the most common exogenous nor 
from endogenous compounds. Our procedure can offer a rapid, precise and accurate method for 
GHB determination in innovative biological fluids, which could be important for screening 
purposes in routine clinical analysis. 
Since the outcome of alcoholic withdrawal therapy is highly variable depending on different 
factors, such as individual metabolism, it is of principal importance to accurately determine GHB 
blood levels in order to optimize the dosage in each subject. The developed method allows to 
perform TDM of patients under Alcover® treatment with all the advantages offered by DBS 
technique, including low invasiveness of the sampling procedure and low cost of sample 
collection, transport and storage. 
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5. ANALYSIS OF ADULTERANTS 
PRESENT IN STREET DRUGS BY CE-
DAD 
 
 
 
5.1. Introduction 
 
 
 
The presence of pharmacologically active adulterants in seized illicit drugs is common, and 
many of these substances can cause unwanted local and systemic reactions, therefore contributing 
to the overall toxicity of the "street drug". 
Due to this situation, the analytical information derived from the analysis of street drugs is 
very important for legal and crime investigation purposes. Capillary electrophoresis (CE) is well 
suited for the analysis of illicit drugs: it can separate a wide variety of solutes with high 
efficiency and selectivity, including highly polar, thermally labile and/or non-volatile compounds 
which could prove difficult to analyse via gas chromatography (GC) and high performance liquid 
chromatography (HPLC)
38
.  
The aim of this study is the development of a micellar electrokinetic chromatography (MEKC) 
method suitable for the analysis of several different basic, acidic and neutral solutes, for the 
purpose of screening adulterants in seized substances.  
The proposed method uses a BGE containing SDS in phosphate buffer, a 48.5 cm uncoated 
fused silica capillary and a photodiode array (PDA) detector set at 233 nm. It is capable of 
discriminating atropine, lidocaine, quinidine, acetaminophen, scopolamine, caffeine, 
theophylline, salicylic acid and tetramisole in their mixtures. 
The illicit market of drugs of abuse is constantly evolving and the active ingredients, 
especially when they reach a status relevant business, may be subject to adulteration and 
sophistication.
39
  
The main reason that pushes to dilute drugs is economic. In fact the so-called "cut" allows cost 
reduction in production that has as a direct result of the increase in profits of drug traffickers
40
. 
The knowledge of the impurities present in street drugs, "street drugs", it is important for the 
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understanding of the phenomena of "accidental overdose" of unexpected side effects and routes of 
distribution to various countries
41
 
Among these are harmless diluents such as sugars, but also substances that induce a 
physiological response defined adulterants and processing residues, contaminants. 
Substances that have a pharmacological, that mimic or enhance the effects of the drug are 
considered adulterants.  
Adulterants can be in any illegal substance, at any concentration. It is important to recognize 
the presence of these substances when a person has a "mixed picture", a manifestation of unusual 
side effects, after taking an illegal substance. The synergistic effect produced by the presence of 
adulterants in the composition of "street drugs" can be a determining factor in the pathogenesis of 
acute intoxication by drugs as well as a previous or concomitant use of other substances such as 
alcohol or drugs may amplify the toxicity .Adulterants used are countless variations and ever 
new, difficult to categorize in analysis laboratories. For the Police Forces, tracking drugs requires 
constant updates and high costs: the lists of prohibited substances, despite efforts in the media and 
in research, are not always complete and still differ from state to state
42
. The content of 
adulterants increases in the various steps of the distribution chain
43
. 
The main adulterants properties are reported in table 8. 
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Adulterant Street Drugs legal use Potential as adulterant toxicity 
Caffeine Heroine, Cocaine, 
Amphetamine 
Stimulant psychoactive effect, 
essentially legal, economic, 
easily available, facilitates 
vaporization heroin; 
Anxiety, mood disorders and sleep 
disorders; 
Malignant syndrome MDMA 
Paracetamol Heroine Anti inflammatory substance readily available, 
inexpensive analgesic 
properties similar to heroin 
Gastro-intestinal disorders, damage to 
the liver Adri, interaction with alcohol 
Quinine, quinidine Heroine, cocaine Antimalarial, anti-
arrhythmic 
Bitter taste similar to heroin, 
mimics the rush respiratory 
heroin injection 
Kidney damage, cinconism, gastric 
disorders, thrombosis,  
Scopolamine Heroine Anticholinergic 
alkaloid, 
spasmolytic 
mydriatic, 
Colorless, tasteless, odorless, 
and not easily detectable, 
amnesia, impaired vision, 
relaxing 
Low doses cause drowsiness; high 
doses cause euphoria 
Hallucinations, dry mouth, 
tachycardia 
Atropine Heroine mydriatic, impaired vision, relaxing Hallucinations, dry mouth, 
tachycardia 
Lidocaine, 
procaine 
Cocaine Local anesthetic, 
antiarrhythmic 
 
Anesthetic effects similar to 
those produced by cocaine 
Cardiovascular and CNS; Increases 
toxicity of cocaine. Nausea, vomiting, 
dizziness, tremors, convulsions 
Tetramisole Cocaine anthelmintic active metabolite aminorex 
CNS stimulant, increasing 
dopaminergic trasmmission 
Highly toxic. Fever, agranulocytosis 
diphenhydramine Cocaine, heroine antihistamine perception of better quality of 
drugs 
euphoria, disorientation, drowsiness 
appetite 
effect gastrolesivo 
Acetylsalicylic 
Acid 
MDMA, heroine anti-inflammatory, 
antipyretic, 
anticoagulant 
perception of better quality of 
drugs, mitigates the negative 
effects (headache) 
ulcer 
 
Table 10. Main adulterants properties 
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The opportunity to determine the content of adulterants in "street drugs" has always aroused 
great interest especially the implications in terms of legal and investigation and has seen the use 
of different analytical methods
44
. 
The first analyzes that are performed on samples of drugs usually using colorimetric 
techniques. These tests are often performed on the raw sample before going to isolate individual 
compounds. For the identification of heroin, morphine, amphetamine, methamphetamine and 
ecstasy using the Marquis reagent while for cocaine using the reagent of Scott. These substances 
can also react with adulterants for which they are requested analytical further confirmations
45
. 
The direct identification and screening of mixtures of many substances of abuse and 
adulterants was carried out using techniques of infrared spectroscopy (IR)
46
. The IR spectrum 
produces a pattern that is unique in that it bound to the chemical structure of the drug and can be 
compared with a reference. Some authors consider the fact IR as a method of identifying 
"fingerprint". This method, however, has limitations: to obtain a spectrum acceptable sample 
must be very clean and free of debris watery. This means that to use this method at the legal level 
is often necessary to resort to extraction processes to remove impurities, consequently extending 
the analysis time. 
Numerous methods developed for the analysis of adulterants in the literature involve the use of 
gas chromatography, usually coupled to a flame ionization detector (GC-FID)
47
. This is a 
standard technique for forensic investigations in the last three decades
43
. In 2003 was published a 
research which used this method for the identification and quantification of cocaine and 
adulterants detected in powder seized in Brazil
44
. A subsequent publication has shown the ability 
to optimize and harmonize the analytical data obtained from two different GC-FID in two 
different laboratories, in France and in Switzerland in order to draw a profile of the samples of 
cocaine
41
. This method, however, does not allow the analysis of non-volatile compounds that you 
might be present in dust from the road, certain thermolabile substances can undergo thermal 
degradation due to phenomena of catalytic pyrolysis, some substances requiring chemical 
derivatization and the analysis involves high costs. In addition, the FID detector has limits 
because it allows to detect only the compounds that can burn. Other components can be ionized 
by passing along the flame, but could not produce a signal strong enough to be detected by the 
instrument
48
. 
The GC method is used mainly coupled to the mass spectrometer (GC-MS) for the analysis of 
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samples of heroin and cocaine. A recent study reported the purity, the concentration range and 
frequency of use of adulterants in 471 samples of 962 cocaine and heroin seized in 
Luxembourg
40
. This allowed us to estimate the variation of these substances in the years and 
speculate about their origin. 
New analytical methods have also been developed in high-performance liquid chromatography 
(HPLC) coupled with various detectors; Therefore, it has been possible to perform new analysis 
more reliable for the determination of the concentration of adulterants in various powders sold in 
the street. It is often used a reverse-phase chromatography in which the separation takes place in a 
adulterants C8 or C18 column with a mobile phase polar such as methanol, acetonitrile, THF or 
acid solutions and the elution is carried out according to gradient
49
. In 2009 different samples of 
cocaine were analyzed by reverse phase HPLC with electrochemical detector with accurate 
results. This proposed method has proved particularly convenient and suitable for routine analysis 
of samples of substances of abuse seized. The HPLC method-DAD
49
  uses multiple wavelengths 
and allows to highlight the potential presence of adulterants in all samples examined. In this way 
it is possible to perform a monitoring of these with savings in terms of analysis time and cost. 
Although some HPLC methods are advantageous because they can simultaneously analyze 
abuse substances, impurities and adulterants, also have some disadvantages including the 
resolution of peaks limited. Furthermore, the basic compounds, acids and some neutral substances 
are separated in the same region as the chromatographic lipophilicity of the solute (log P) plays a 
predominant role in the mechanism of separation.Other methods developed for the analysis of 
adulterants in the literature involve the use a liquid chromatography coupled to the mass 
spectrometer (LC-MS). 
The capillary electrophoresis (CE), in offers important advantages over HPLC and GC 
including excellent separative efficiency of complex samples, rapid analysis, a reduced 
consumption of samples and of organic solvents, an instrumentation simple and more resistant, 
and various modes of separation suitable for the determination of a large number of analytes: very 
polar substances, heat-labile, and non-volatile compounds. As a result, the EC has been widely 
used in quality control and monitoring therapeutic drug but still little used in the legal and 
forensic.  
Since adulterants are substances of various nature (different charge, different different 
lipophilicity and pKa) it was considered appropriate to develop an electrophoretic technique that 
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exploits these characteristics to improve separation. The method MEKC is the most appropriate 
because it takes the advantages of the EC and those of HPLC in a single system. 
 
 
 
5.2. Experimental 
 
 
Chemicals 
 
Paracetamol, acetylsalicylic acid, the tetramisole, quinidine, diphenhydramine, atropine, 
scopolamine, lidocaine and caffeine were supplied by Sigma Aldrich (St. Louis, Missouri, USA), 
sodium dodecyl sulfate (SDS), lactose, starch and the solutions of methanol, and ethanol were 
purchased from the same company, the disodium hydrogen phosphate and phosphoric acid were 
produced by Carlo Erba (Milan, Italy). The L-sulpride (N - [[(2S) -1-etilpirrolidin-2-yl] methyl] -2-
methoxy-5-sulfamoilbenzammide) 4 used as the internal standard (IS, Figure ) was supplied by 
Sigma Aldrich (St. Louis, Missouri, USA). 
The ultrapure water (18.2 MΩ cm) was obtained using a Milli-Q system supplied by Millipore 
(Milford, Massachusetts, USA) 
 
 
Figure 17. L Sulpiride structure 
 
Preparation of stock and working solutions 
 
The stock solutions of adulterants were prepared by weighing 1.00 mg of the substance and 
solubilizzandola in 1,000 mL of methanol. The stock solution of sulpiride was prepared by 
weighing 1.00 mg of the substance and solubilizing in 1,000 mL of methanol. 
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Both stock solutions were diluted to the desired concentrations using the BGE (Back Ground 
Electrolyte) to obtain working solutions. All solutions were stored in a freezer at -18 ° C. The 
backgound electrolyte (BGE) is constituted by a benzoate buffer 15 mM at pH 5.5 containing 0.5 
mM CTAB and MeOH to 30% (v / v). 
The BGE consists of 12.5 mM phosphate buffer at pH = 8.5 + 25 mM SDS. The phosphate 
buffer was prepared in the following way: were weighed 88.72 mg of dibasic sodium phosphate and 
were dissolved in about 15 mL of ultrapure water; the solution was then brought to the desired pH 
with a solution of concentrated phosphoric acid freshly prepared and finally the volume was 
brought to 50.0 mL with distilled water. Subsequently, 5.0 mL of buffer were used to solubilize 
36,05 mg of SDS. 
The solution was then filtered with filters of regenerated cellulose with a pore diameter of 0.20 
µm. 
 
 
Simulated sample preparation 
The powder samples were prepared by reproducing the composition of street drugs reported in 
literature due to seizure of the police. The percentages of diluents and adulterants were reproduced 
exactly. The drug was not present instead (simulated sample). The "cut" occurred by means of 
geometric dilutions 
 
 
Sample pre-treatment 
The pretreatment of the powders from simulated strret drugs is carried out by extraction with 
methanol. Are weighed 50.0 mg of powder to which is added 1.00 mL of methanol. The mixture is 
left under stirring at room temperature for a total time of 30 min. After 10 min, the heterogeneous 
mixture is centrifuged for ten minutes at 4000 rpm, the supernatant is recovered and the residue is 
done two more extractions with 1.00 mL of methanol. The three solutions are then combined in a 
test tube. They are then taken 100 L of methanol solution and diluted 1:10 in BGE. Before 
injection into the EC solution is filtered with filter regenerated cellulose by 0.20 m. 
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Equipment 
 
The instrument used for the analysis is a capillary electrophoresis system (CE-3D, Agilent, Palo 
Alto - CA, USA) equipped with a photodiode array detector (DAD)set to 218 nm, 233nm, 274nm. 
The separation was conducted using a fused silica capillary (Composite Metal Services, Hallow 
UK) with the following characteristics: total length (TL) of 48.5 cm, effective length (EL) of 40.0 
cm and internal diameter (ID ) of 50 microns. 
The samples were injected from the anode side of the capillary by means of a pressure of 50 
mbar for 10s. 
The applied voltage was 20 kV. The wavelength of 210 nm was set for detection. 
At the beginning of each day, the capillary was conditioned with ultrapure water, 1N NaOH, 
ultrapure water and BGE, for ten minutes each.  
A Crison (Barcelona, Spain) MicropH 2000 pHmeter, a Hettich (Tuttlingen, Germany) Universal 
32 R centrifuge and an IKA (Staufen, Germany) RV 10 rotary evaporator were also used. 
Data were handled by means of ChemStation software from Agilent (Santa Clara, CA, United 
States). 
 
 
Method validation 
 
The method was validated according to USP XXXVIII26
26
 and “Crystal City”27 guidelines. 
 
 
- Linearity, limit of quantitation, limit of detection 
 
Aliquots of 10 µL of analyte standard solutions at six different concentrations, containing the IS 
at a constant concentration, were added to 100 µL of BGE. The resulting calibration standards were 
subjected to the previously described pretreatment procedure and then injected into the CE system. 
Calibrators were prepared in triplicate for each point and covered the following plasma range: 2.0-
320 µg mL
-1
. The concentration of the IS was 10 µg mL
-1
. The analyte/IS peak-area ratios obtained 
were plotted against the corresponding concentrations of the analytes (expressed as µg mL
-1
) and 
the calibration curves were constructed by means of the least-square method. 
The limit of detection (LOD) and limit of quantitation (LOQ) were calculated as the analyte 
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concentrations which give rise to peaks whose heights are 3 and 10 times the baseline noise, 
respectively. 
 
 
Extraction yield and precision 
 
For these assays simulated samples at three different concentrations of the analytes, 
corresponding to the lowest, the intermediate and the highest point of the calibration curve, were 
prepared. The samples, containing 2.0, 50.0 and 100.0 µg mL
-1
 of adulterants were subjected to the 
previously described pre-treatment procedure and injected into the CE. The analyte peak areas of 
the spiked samples were compared to those obtained injecting standard solutions at the same 
theoretical concentrations and the extraction yield (expressed as percentage value) was calculated. 
The assays described above were repeated six times within the same day to obtain repeatability 
(intraday precision) and six times over six different days to obtain intermediate precision (interday 
precision), both expressed as percentage relative standard deviation values (RSD%). 
 
 
- Selectivity 
 
The selectivity of the method was evaluated with respect to exogenous compounds. Selectivity 
towards exogenous substances was investigated by injecting into the CE system standard solutions 
of several compounds that could be co-administered in clinical practice. A substance was classified 
as interfering if it gave rise to a peak that was not baseline separated from those of the analytes or 
the IS. 
 
 
- Stability 
 
Stock solution stability was tested by comparing the analyte/IS peak-area ratios of a standard 
solution (containing 10 µg mL
-1
 of adulterants) prepared from stock solutions stored for 1 month at 
-20°C with those of a standard solution at the same theoretical concentrations obtained from  fresh 
stock solutions (n = 3). Stability assays were also carried out in blank plasma samples fortified with 
10 µg mL-1 of adulterants. Sample stability was evaluated over five hours at room temperature, 
after three freeze- thaw cycles and after 1 month of storage at -80°C (n = 3 per storage condition).  
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- Analysis of street drugs simulated samples  
.  
The validated method was applied to quantify the content of adulterants in dust samples from 
simulated street drugs to the solutions was added the internal standard to the constant concentration 
of 10 g / mL. 
 
 
- Accuracy 
 
The accuracy was evaluated by performing recovery tests, adding known amounts of standard 
solutions of the analytes methanol extract diluted in BGE. The concentrations were added to 5 µg / 
mL, 10 µg / mL and 15 µg / mL whose analyte concentrations had been previously determined (n = 
3 for each level); then, the mixtures were subjected to the pretreatment procedure. Accuracy was 
expressed as percentage recovery and was calculated according to the following formula: 100  
([after spiking] – [before spiking]) / [added], where [after spiking] is the sum of the concentrations 
of the analyte in the real plasma and in the analyte standard solution added; [before spiking] is the 
concentration of the analyte in the real sample; and [added] is the concentration of the analyte 
standard solution added to the real sample. 
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5.3. Results and discussion 
 
 
Development of electrophoretic conditions 
 
Normally the electrophoretic analyzes are conducted in an aqueous environment. In the 
electrophoresis capillary zone (CZE) separation of the analytes takes place by differential migration 
of charged species (ions) in a buffered solution, for the effect of the application of an electric field 
inside the capillary.Some of adulterants considered, however, are quite lipophilic molecules, 
without fillers and with a high degree of unsaturation.So the CZE does not lend itself to the analysis 
of this type of molecules as the relative mobility is equal to zero. The development of strategies that 
allow the use of capillary electrophoresis for the determination of substances of this type has been a 
critical step in the development of the method.The approach was systematic. 
• First you are looking for the ideal pH conditions to favor the formation of a strong 
electroosmotic flow such as to allow the migration of the analyte towards the detector. 
• Then it is tried to improve the mobility of some analytes in BGE with the addition of 
additives loads: β-cyclodextrin sulfate and SDS. 
• Finally, there was the effect of additives on the mobility of all analytes.Considering the 
structures of the compounds it was considered appropriate to operate at a basic pH, in order to 
exploit the establishment of a strong electroosmotic flow (EOF). The choice of the BGE and then 
was carried out by evaluating the pKa of the acids used in the preparation of the pad.The various 
tests were carried out using phosphate buffer (pKa = 7.20), TRIS buffer (pKa = 8.10), carbonate 
buffer (pKa = 9.70) and borate buffer (pKa = 9.23). The carbonate buffer was discarded because it 
has not produced a stable current and reproducible over time.The best result was obtained with 
phosphate buffer, which was tested at various concentrations (from 10 mM to 30 mM) and at 
various pH (7.00 to 9.00), leaving unchanged the percentage of additive in order to obtain the better 
mobility of the analyte compared to that of 'EOF. The optimal concentration of the buffer is 12.5 
mM and was prepared using dibasic sodium phosphate, ultrapure water and a solution of phosphoric 
acid to lower thestarting  pH .Subsequently were tested increasing concentrations of sodium 
dodecyl sulfate (SDS from 10 mM to 50 mM) to favor the formation of micelles and assess the 
interaction of the analyte with them. For low quantities was observed a low, if any, interaction, 
while an excessively high percentage the base line was not stable due to the increase of the charges 
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present in the BGE. The optimal concentration of SDS was found to be 25 mM. In place of the 
sodium dodecyl sulphate was also tested -CD sulphate in percentage ranging from 0.5% to 1.5% 
(w / v) without obtaining meaningful results. The BGE chosen for analysis, then, consists of a 12.5 
mM phosphate buffer at pH 8.5 + 25 mM SDS. Even the voltage has been the object of numerous 
tests based on the percentage of surfactant to obtain the analysis in the shortest possible time. The 
chosen final voltage is 20 kV, which guarantees a stable and consistent current around 70mA.The 
temperature of the capillary was maintained constant at 25 ° C and, despite this, it was revealed that 
the total travel time tended to increase in the course of the day, probably due to the aging of the 
BGE.The injection of samples was performed by the anode side with a pressure of 50 mBar for ten 
seconds. Subsequently, the injection time was increased up to twenty seconds, to improve the 
sensitivity in the quantification of the analyte. For injection times greater were detected 
deterioration in the selectivity, as the peak appeared scodato.The procedure of pre-conditioning and 
post-conditioning consists in flushing the capillary with BGE for two minutes. Although the solvent 
for dilutions of the solutions to be injected in the EC has been the subject of study; dilutions 
prepared using solvents such as water and phosphate buffer gave peaks with areas and little 
reproducible migration times. The best results were obtained by diluting the substances with the 
BGE. 
 
 
Internal standard selection 
 
The internal standard is a substance that from the chemical point of view must be sufficiently 
different from the analyte, so as to be able to be determined, in the same experiment, without 
interfering in the measurement. Also his recovery should reflect that of the test species. So the 
selected molecule should be quite lipophilic and at the same time must not be used as an adulterant 
in the street drug to avoid interference. 
Initially were analyzed propranolol, which has a migration time very close to that of atropine, 
amiloride and benserazide, which have migration times are too long; subsequently tiapride, L-
sulpiride and amisulpride. 
Among these was chosen the L-sulpiride that has a migration time and the intermediate is not 
present in the samples of street drugs 
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Linearity 
 
Having developed the electrophoretic conditions, we moved to the validation of the method 
of standard solutions. The area under the curve of the peak electrophoretic each analyte is directly 
proportional to its concentration. To assess the linearity range of the method, mixtures were 
prepared at different concentrations of analytes, keeping constant the internal standard L sulpiride to 
(tm = 6.3 min) to 10 µg / mL and were injected into the CE (Figure 16) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. mix standard of adulterants: 1Caffeine, 2 Lidocaine,3 Paracetamol, 4Acetylsalicylic Acid,5 Scopolamine,6 Atropine, 7 
Tetramisole, 8 Quinidine, 9 Diphenhydramine 10 ug mL 
 Then the calibration curve of the analyte concentration range were buit between 5 and 150.0 g / mL 
(Table 9), plotting the relationship between the peak areas of the analyte electrophoretic and those 
of the internal standard peak, in function of the concentration of the analyte. The equation of the 
line obtained by interpolation was calculated by the method of least squares.  
The repeatability of the method was verified by running six tests on standard solutions at 
different concentrations of adulterants in the same day. These solutions correspond to the lower 
limit, to an intermediate point and a high point of the calibration curve. To simplify the work, were 
injected mix of all analytes for each test (Table 10) 
To evaluate the interday precision of the method, the same concentrations of standard 
solutions were injected in 6 different days (Table 11) 
  
 1 
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Table 11 Linearity parameters 
 
 
 
 
  
Analytei Tm (min) 
Range  
(µg/mL) 
 
y = ax + b r2 
LOD  
(µg/mL) 
a b 
Caffeine 2.3 5-150 1.473 -0.032 0.9997 1.5 
Lidocain 2.7 5-150 1.376 0.012 0.9995 1.5 
Paracetamol 2.9 5-100 2.838 0.004 0.9996 1.5 
Acetylsalicylic Acid 3.8 10-150 0.801 0.003 0.9991 3.0 
Scopolamine 4.4 5-100 1.239 0.014 0.9993 1.5 
Atropine 4.6 15-150 0.539 -0.003 0.9992 5.0 
Tetramisole 5.3 10-150 0.940 0.003 0.9992 3.0 
Quinidine 7.4 5-100 2.400 0.005 0.9995 1.5 
Diphenhydramine 7.9 5-100 1.222 0.005 0.9994 1.5 
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Analyte 
Migration 
time 
(min) 
Concentration 
(µg mL-1) 
Intraday precision, 
Area Ratio analyte/I.S. 
(R.S.D.%) 
Migration 
Time 
(R.S.D.%)a 
Caffeine 
 
2.3 
5 3.80  
2.0 
 
50 2.10 
150 1.49 
Lidocaine 2.7 
5 3.20 
1,7 50 2.50 
150 1.75 
Paracetamol 
 
2.9 
5 3.17 
1.8 
 
10 2.06 
50 1.08 
Acetylsalicylic ac 
 
3.8 
10 4.07 
1.1 
 
50 3.00 
100 2.73 
Scopolamine 4.4 
5 3.15 
2.3 50 3.00 
100 2.78 
Atropine 
 
4.6 
15 3.13 
2.0 
 
50 3.09 
100 2.85 
Tetramisole 
 
5.3 
10 3.10 
1.8 
 
50 2.04 
100 1.14 
Quinidine 
 
7.4 
5 3.09 
0.9 
 
10 3.00 
100 1.47 
Diphenhydramine 
 
7.9 
5 3.04 
2.02 
 
10 3.03 
50 2.00 
 
Table 12 Intraday precision 
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Analyte 
migration 
time 
 
Concentration Interday Precision 
 (min) (µg.mL-1) 
Area Ratio 
analyte/I.S. 
(R.S.D.%) 
Migration 
Time (RSD%)b 
Caffeine 
 
2.3 
5 5.08 
3.2 50 5.00 
150 3.90 
Lidocaine 2.7 
5 4.90 
2.7 50 3.89 
150 4.01 
Paracetamol 
 
2.9 
5 5.07 
3.1 10 4.06 
50 3.00 
Acetylsalicylic ac 
 
3.8 
10 5.07 
3.1 50 4.00 
100 4.02 
Scopolamine 4.4 
5 5.02 
2.9 50 4.00 
100 3.87 
Atropine 
 
4.6 
15 6.03 
3.0 50 5.09 
100 4.05 
Tetramisole 
 
5.3 
10 5.00 
3.4 50 4.04 
100 3.04 
Quinidine 
 
7.4 
5 5.09 
2.3 10 4.00 
100 3.08 
Diphenhydramine 
 
7.9 
5 6.03 
3.0 10 5.03 
50 3.00 
Table 13 Interday precision 
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-  Application to simulated street drugs 
 
The validated method was applied for the control of dust samples from simulated road or 
prepared in the laboratory trying to reproduce the composition of the major national and 
international drug seizures reported in the literature. The results are expressed in mg of adulterants 
of grams of powder from the road. Note that the diluents (such as starch and lactose) precipitated 
during the step of pretreatment of the sample and do not interfere with the electrophoretic system. 
The results of analyzes carried out on samples of dust from the road simulated are 
summarized in Table . 
Sample A reproduces the content of adulterants present in seizures of cocaine and heroin 
made in Luxembourg from 2005 to 2010.Figure 17 
The sample B simulates the content of adulterants in cocaine seizures made in France in 
2006.Figure 18 
The sample C follows the composition of adulterants in cocaine seizures made in Brazil in 2003.26 
In the sample D are the same as adulterants of seizures made in Switzerland and France from 2004 
to 2005.6 
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Figure 19. Sample A: 3 Paracetamol, 4Acetylsalicylic Acid,6 Atropine 
 
 
Figure 20 Sample B3 Paracetamol, 9 Diphenhydramine 
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Table 14results in simulated  street drugs 
-  
 
-  
  
 Campione 
simulato A 
Campione 
simulato B 
Campione 
simulato C 
Campione 
Simulato D 
Caffeine x x 47,0 mg/g x 
Lidocaine x x 35,0 mg/g x 
Paracetamol 24,0 mg/g  10,5 mg/g x x 
Acetilsalicilic 
Acid 
21,0 mg/g   x x x 
Scopolamine x x x 5,10 mg/g 
 
Atropine 34,3 mg/g  x x x 
Tetramisole x x x 4,70 mg/g 
Quinidine x x 15,2 mg/g x 
Diphenhydramine x 30,5 mg/g  x x 
72 
 
 
 
- Accuracy 
To complete the validation of the method, tests have been performed of accuracy that has 
been evaluated by performing recovery tests by adding a standard solution of known concentration 
of each analyte to solutions of the samples previously analyzed. 
The additions were made considering three different concentrations: 5 mg / mL, 10 mg / mL 
and 15 mg / mL. 
The recovery values found were always superior to 88% for all analytes, then the accuracy 
of the method is good. 
These results are reported in Table 13 
 
Table 15 accuracy  
 Recovery % 
 
added 
5 µg/mL 
added 
10  µg/mL 
added 
15  µg/mL 
Caffeine 89 90 88 
Lidocaine 108 93 97 
Paracetamol 97 92 98 
Aaceylsalicylic 
Acid 
105 90 88 
Scopolamine 90 95 94 
Atropine 88 90 89 
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5.4. Conclusions 
 
The illicit use of drugs of abuse has always been a serious health risk. However, the toxic 
action and special events that can be observed in the individual adverse that makes use of common 
street drugs are often a result of the synergy of drugs with the substances to be "cut".  
The presence of adulterants is often neglected by a clinical point of view-toxicological so it 
is important to have precise and selective methods for the analysis of these substances, commonly 
added to street drugs, in particular: caffeine, acetaminophen, atropine, scopolamine, lidocaine, 
diphenhydramine, levamisole, acetylsalicylic acid, quinidine. In this thesis has been developed a 
method in capillary electrophoresis, with detector photodiodes, innovative and reliable using the 
principles of the MEKC (Micellar electrokinetic Chromatography) for the analysis of adulterants in 
samples of street drugs simulated. 
The system proposed MEKC showed high efficiency, low cost, and versatility. Moreover, 
given the reduced consumption of organic solvents, can be considered a technique "green", which 
aims to minimize the environmental impact.  
The pretreatment procedure of the sample is simple and fast and allows to obtain high 
recoveries with a good purification of the matrices of the interference.  
The preparation of the BGE is rapid and highly reproducible. For the validation of the 
method were performed numerous tests, both on standard solutions, both on simulated samples of 
interest. The results are satisfactory, having obtained a good linearity (R2> 0.9991) and a high 
precision for all analytes in exams (RSD values of less than 6.03%) and a good accuracy (recoveries 
higher than 88% ). 
The method MEKC proposal for analysis of adulterants in simulated street drugs seems, 
therefore, suitable to be applied to the analysis of real samples seized by the Police Forces.This type 
of investigation can be useful for monitoring the trends of consumption for the purpose of human 
health, in the case of new discoveries of adulterants and contaminants 5 
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6. DEVELOPMENT OF A CONFIRMATORY HPLC 
MS/MS METHOD FOR THE ANALYSIS OF 
GLUCOCORTICOIDS IN HUMAN URINE  
 
 
6.1. Introduction 
 
Glucocorticoids are steroid hormones, that inhibit the process of inflammation. Natural 
glucocorticoids are produced in the adrenal glands located immediately above the kidneys in the 
cortex as a defensive reaction to the damage or injury of the tissues. Physiologically, they 
contribute in several metabolic regulations, above all in the glucose and lipid metabolism. 
Synthetic glucocorticosteroids used in medicine are analogs and derivatives of natural hormones. 
Glucocorticosteroids have found wide use in contemporary sport as powerful anti-inflammatory 
agents for the treatment of bronchial asthma and for the therapy of acute and chronic soft tissue and 
joint injuries. Synthetic corticosteroids can produce a number of serious side effects as they are 
more active than their natural analogs. The misuse of coticosteroids can lead to    
immunodeficiency; hyperglycemia due to increased gluconeogenesis, insulin resistance, and 
impaired glucose tolerance; reduced bone density (osteoporosis, osteonecrosis);  weight gain due to 
increased visceral and truncal fat deposition (central obesity) and appetite stimulation;    
hypercortisolemia (also known as, exogenous Cushing's syndrome); muscle breakdown 
(proteolysis). 
 The effects on the central nervous system are less considered but very important. The 
prolonged use of glucocorticoids can produce excitatory effect on central nervous system 
(euphoria, psychosis) and impaired memory and attention deficits
50
 
Glucocorticoids act on the frontal lobes amygdala and hippocampus. Along with adrenaline, 
these enhance the formation of flashbulb memories of events associated with strong emotions, both 
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positive and negative
51
. In fact,  the block of either glucocorticoids or noradrenaline activity 
impaired the recall of emotionally relevant information. Additional sources have shown subjects 
whose fear learning was accompanied by high cortisol levels had better consolidation of this 
memory . The effect that glucocorticoids have on memory may be due to damage specifically to 
the CA1 area of the hippocampal formation. In multiple animal studies, prolonged stress (causing 
prolonged increases in glucocorticoid levels) have shown destruction of the neurons in this area of 
the brain, which has been connected to memory performance
52
. Glucocorticoids have also been 
shown to have a significant impact on vigilance (attention deficit disorder) and cognition 
(memory).
53
 Long-term exposure to glucocorticoid medications, i.e asthma, has been shown to 
create deficits in memory and attention both during and after treatment, a condition known as 
"steroid dementia."
54
 
Particularly dangerous is the uncontrolled and incorrect use of these compounds by sportsmen 
during competitions. As a result, synthetic corticosteroids were added to the list of banned doping 
substances  by the World Anti-Doping Agency (WADA)
55
 . These rules state that glucocorticoids 
levels must be detectable at 30 ng/mL. 
Several methods can be found in the literature for the detection of glucocorticoids: 
radioimmunoassay
56
, 
57
, fluorimetric
58
, 
59
, and  HPLC  with  UV  detection 
60
,
61
. Despite their 
rapidity, these methods lack the sensitivity and selectivity needed for doping control. Glucocor- 
ticosteroids can also be assayed by gas chromatography with mass spectrometry
62
,
63
. A significant 
limitation of this method is the necessary and laborious stage of preparing volatile 
methoxyiminetrimethylsilyl derivatives. Glucocorticosteroids are currently assayed by HPLC 
combined with mass spectrometry, where there is no need for the derivatization stage
64
,
65
. This 
methods have high sensitivity and selectivity bu the literature currently lacks reliable data on the 
simultaneous screening analysis of the main glucocorticosteroids, including isobars. 
The aim of the present work was to develop a development of a confirmatory method for the 
analysis of  22 glucocorticoids in human urine according to World Anti-Doping Agency (WADA) 
criteria. 
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Abstract 
 
Initially isobaric analytes (that require chromatographic separation) were selected to identify the 
best stationary and mobile phase conditions to allow chromatographic separation.  
A C18 column and a gradient of aqueous and organic solvents for a reversed-phase chromatography 
was used.  
I evaluated the flow rate and gradient profile to obtain baseline separation of the chromatographic 
peaks. Finally I included the remaining analytes to check the suitability of the chromatographic 
method. 
Concerning MS, a full optimisation of source parameters and collision energy values was 
performed.  
For each analyte, a product scan spectrum was acquired to identify the most suitable ion transitions 
to be used for identification, which was then performed in SRM mode in the final method.  
A mixed-mode SPE cartridge was used for sample pre-treatment, following deconjugation using β-
glucuronidase. Validation of the method in terms of linearity, precision and accuracy was carried 
out.  
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6.2. Experimental 
 
 
 
Chemicals 
 
Standard stock solutions were purchased 
from Cerilliant (Round Rock, TX, USA). All standards were methanolic solutions, 
its deuterated internal standard (IS) that were dissolved in methanol/water (1:1). 
Ammonium acetate was obtained from Sigma Aldrich (St. Louis, MO, USA). 
Ammonium hydroxide and concentrated formic acid were from Fisher Scientific 
(Pittsburgh, PA, USA). HPLC grade methanol was purchased from J.T. Baker 
(Phillipsburg, NJ, USA). Ultrapure water (18.2 MΩ cm) was obtained by means of a 
MilliQ apparatus by Millipore (Milford, MA, USA). Human blank plasma was from the 
University of Utah blood bank. 
 
 
Preparation of working solutions 
 
Calibrator working solutions containing all analytes were prepared by diluting 
standard stock solutions with methanol/water (50:50, v/v). Separate working solutions 
were prepared in the same way for QC samples. A deuterated internal standard (IS) 
working solution was prepared in methanol/water (50:50, v/v) at a concentration of 0.1 
μg mL
-1
. All working solutions were stored at -20°C. Stock solutions were stable for at 
 
least 4 months when stored at -20 °C (as assessed by HPLC assays). 
 
 
 
Preparation of calibration standards and quality control samples 
 
Calibration standards were prepared daily by adding the appropriate aliquot of 
calibrator working solutions and 30 µL of deuterated IS working solution to 1 mL of 
blank u r i n e  Calibrators were at the followingu r ine  concentrations: 0.2, 0.5, 1.0, 
5.0, 20.0, 50.0, 75.0 and 100.0 ng mL
-1
In the same way, quality
78 
 
 
 
 
control (QC) samples were prepared by adding the appropriate amount of QC working 
solutions and 30 µL of deuterated IS working solution to 1 mL of blank u r i n e . QC 
samples were at three concentration levels: low QC contained 0.6 ng mL
-1
 
; medium and high QC were at a concentration of 10.0 and 85.0 ng mL
-1
, respectively, 
for all analytes. 
 
 
 
Equipment 
 
LC–MS/MS analyses were performed using an ACQUITY UPLC
® 
system (Waters, 
Milford, MA, USA) coupled to a Quattro Premier XE™ triple quadrupole mass 
spectrometer (Waters). Solid phase extraction (SPE) was carried out on Oasis MCX 
cartridges (60 mg, 3 mL) (Waters) using a Vac Elut manifold. A Thermo Scientific 
(Waltham, MA, USA) IEC FL40 floor centrifuge and a Zymark (Hopkinton, MA, USA) 
TurboVap
® 
evaporator were also used. 
 
Data were handled with MassLynx™ (v 4.1) software (Waters). 
 
 
 
LC-MS/MS conditions 
 
The chromatographic separation was achieved on a Supelco (Bellefonte, PA, USA) 
Discovery
® 
HS F5 column (2.1 x 50 mm, 3 µm) held at 40°C. The mobile phase 
consisted of 10 mM ammonium acetate containing 0.1% formic acid (A) and methanol 
(B). The flow rate was kept constant at 0.25 mL min
-1 
and a gradient program was run. 
Initial mobile phase conditions were 90% A and 10% B; B was increased linearly from 
10 to 70% in 6 min, held at 70 % for 0.50 min, decreased back to the initial mobile 
phase condition of 10% B in 0.30 min and finally held at 10% for 4.0 min to re- 
equilibrate the column (total chromatographic run time was 10.80 min). Injections were 
performed with an autosampler maintained at 4°C; injection volume was 12 μL. 
The mass spectrometer was operated in electrospray positive ionization (ESI+) mode 
and performed multiple selective reaction monitoring (MRM). Capillary voltage was 
set at 3.00 kV and source and desolvation temperature were set at 100°C and 350°C, 
respectively. 
Nitrogen was used as the desolvation gas at a flow rate of 800 L h
-1 
while argon was 
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used for collision. Cone voltage and collision energy were optimized for each analyte 
along with the selected MRM transitions. three product ions were monitored for each 
analyte; the most abundant one was used for quantification while the other one was 
used as qualifier. Dwell time was 200 ms for all the other MRM transitions 
monitored. 
 
 
 
 
 
 
 
 
 
 
 
 
Sample pre-treatment: solid phase extraction 
 
Sample pre-treatment was carried out by SPE on  mixed-mode cation-exchange 
cartridges conditioned with 2 mL of methanol followed by 2 mL of water. A 1-mL 
aliquot of u r in e  fortified with the analytes was spiked with 30 µL of deuterated IS 
working solution (0.1 µg mL
-1
) and acidified with 1 mL of ammonium acetate (100 
 
mM, pH 5.0). The resulting mixture was briefly vortexed and centrifuged at 2800 rpm 
for 10 min to remove any particulate material. The supernatant was loaded onto 
previously conditioned cartridges that were then washed with 2 mL of ammonium 
acetate (100 mM, pH 5.0) and 2 mL of methanol. Analytes were eluted with 2 mL of 
10% ammonium hydroxide in methanol and the eluate was evaporated to dryness under 
air at 40°C. Finally, the residues obtained were reconstituted in 75 µL of 0.1% formic 
acid and transferred into autosampler vials. 
 
 
Method validation 
 
The method was validated following the U.S. Food and Drug Administration (FDA) 
guidelines for bioanalytical method validation66 [139]. 
 
 
- Linearity and lower limit of quantitation 
 
Linearity was evaluated over the 0.2-100 ng mL
-1 
concentration range NOXM by 
analyzing in duplicate the calibration standards subjected to the previously 
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described sample preparation procedure. The analyte/IS peak-area ratios were plotted 
against the corresponding concentrations of the analytes (expressed as ng mL
-1
) and the 
calibration curves were constructed by means of the least-square method. 
The lower limit of quantitation (LLOQ) was defined as the lowest concentration of 
the standard curve that can be measured with acceptable accuracy and precision. It was 
assessed by analyzing six fortified samples (each prepared from a different urine 
source) and determining precision (expressed as percentage relative standard deviation 
(RSD%)) and accuracy (expressed as percentage of the nominal concentration). The 
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samples were accepted as LLOQ if RSD% was ≤ 20% and if the mean measured 
concentration was within ± 20% of the theoretical concentration. 
 
 
- Extraction yield, precision and accuracy 
 
Extraction yield was determined for each analyte at the low, medium, and high QC 
concentrations (6 replicate each). QC samples were subjected to the previously 
described pre-treatment procedure and analyzed along with unextracted standard 
solutions prepared at the same theoretical concentrations. The average analyte peak 
areas of the extracted samples were compared to those of the unextracted standard 
solutions and the extraction yields were calculated and expressed as percentage value. 
The data obtained are reflective of the combination of extraction recovery of the 
analytes and matrix effect and they can also be referred to as overall process efficiency, 
according to the definition of Matuszewski et al.67 [140]. 
Intraday accuracy and precision were obtained by analysing low, medium and high 
QC samples five times within the same day; interday accuracy and precision were 
evaluated by analysing the three QC levels 6 times over three different days for a 
total of 18 results per concentration. Intra- and interday precision were both expressed 
as percentage relative standard deviation (RSD%). Intra- and interday accuracy were 
calculated by dividing the mean measured concentrations of the analytes by the 
theoretical concentrations and were expressed as percentage value. 
 
 
- Selectivity 
 
Selectivity was assessed by the analysis of plasma samples from six different healthy 
donors. Each sample was extracted and analysed to determine if any potential 
interference from endogenous components was present at the retention time of the 
analytes and the ISs. In addition, three replicates for each urine source were spiked 
with the ISs and one replicate was spiked with the ISs and the analytes at a 
concentration corresponding to the LLOQ. To be acceptable, the mean peak-area ratio 
of any signal at the retention time of the analytes to the corresponding IS must not 
exceed 20% of the mean analyte/IS peak-area ratio at LLOQ. Moreover, the area of any 
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peak at the retention time of the ISs must be less than 5% of the mean peak area of the 
ISs in the LLOQ samples. 
 
 
- Stability 
 
Stability experiments were performed with low and high QC samples (three 
replicates for each concentration level) stored under various conditions. The stability of 
the analytes in urine samples was evaluated after three freeze-thaw cycles and at room 
temperature. For the assessment of freeze-thaw stability, frozen QC samples were 
allowed to completely thaw unassisted at room temperature and then were frozen again 
for at least 12 h. This was repeated for a total of three times. Room temperature stability 
was evaluated on QC samples left at room temperature for 24 h prior to analysis. 
Stability was also tested in processed samples stored on the autosampler (+4°C) for 5 
days and at -20°C for 7 days. The analytes were considered stable under the tested 
conditions if the mean concentrations found in the stored samples did not differ from 
the theoretical concentrations by more than ±5%. 
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6.3. Results and discussion 
 
 
 
Development of the chromatographic conditions 
 
The investigated analytes are all quite polar molecules, characterized by Considering 
the relatively low lipophilicity of each compound we decided to try two different 
approaches: in the first one we used a C18 column and a gradient of aqueous and organic 
solvents for a reverse phase chromatography; in the second one we use an HILIC column 
and a with reversed-phase type eluents to further the liquid-liquid partition 
chromatography. 
. Considering the relatively low lipophilicity of each compound we decided to try two 
different approaches: in the first one we used a C18 column and a gradient of aqueous 
and organic solvents for a reverse phase chromatography; in the second one we use an 
HILIC column and a with reversed-phase type eluents to further the liquid-liquid 
partition chromatography. 
About the HILIC we used an Acquity UPLC BEH HILIC 1.7 um 2.1 x 100mm 
Column. Mobile phase was A (acetonitrile & 20 mM ammonium acetate) B (purified 
water & 20 mM ammonium acetate). 
Unfortunately this strategy cannot be used because the column have no retention at all 
on analytes. Even with long time conditioning and changing gradient all analytes elutes 
togheder after one minute. 
A HILIC stationary phase was also tried, but no significant improvements were 
obtained.. A gradient program was applied to optimize resolution of  the analytes and 
total run time.  
MS/MS parameters were optimized by infusing standard solutions of each analyte 
directly into the source along with the mobile phase at initial composition. As the most 
abundant fragment ion corresponded to the loss of water for all analytes, three parent-
product ion transitions were monitored for each compound to improve method 
selectivity; the most intense transition was used for quantification and the other one 
was employed to confirm peak identity. it was the closest eluting peak; for all other 
analytes the corresponding deuterated analogue was employed. 
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Fig. 2 
 
Chromatograms of a standard solution of the analytes (0.5 ng mL
-1
) and the ISs. For 
each analyte three MRM transitions are shown (quantification transition is provided 
first). 
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Development of the SPE 
procedure 
 
As for chromatographic method development, the lipophilicity of the analytes s 
challenged the optimization of the extraction conditions. Various SPE cartridges 
and different procedures were tested. C18 sorbent gave low recovery (< 30%) 
even though the samples were basified before loading to stabilize the analytes in 
their deprotonated, more lipophilic, form. Moderately hydrophobic cartridges (C2) 
could not su fficiently retain hat eluted during the washing step. Better results in terms 
of retention of the compounds were obtained on C8 and hydrophilic-lipophilic 
balance (HLB) cartridges (loading the former in basic conditions). However, none 
of the elution solvents tested (methanol, acetonitrile, acidified methanol) gave 
satisfactory extraction yields that were especially low for. Eventually, mixed-mode 
cation-exchange polymeric sorbent proved to be suitable for the extraction of the 
analytes fr om the matrix. The compounds of interest in their protonated form were 
highly retained by ionic interaction and the elution with basified methanol gave  
encouraging results. Nonetheless, it was necessary to carry out some tests to optimize 
the recovery of  
G. Among the solutions investigated, 10% ammonium hydroxide in methanol 
gave extraction yields higher than 70% for all the analytes. In addition, thanks to 
the retention mechanism, it was possible to wash the cartridge with 100% organic 
solvent without affecting the recovery, thus removing also hydrophobic 
interferences and obtaining cleaner extracts. 
The chromatograms of a blank urine sample subjected to the SPE procedure (Fig. 
 
3) show that no significant peaks are present at the retention times of the analytes. 
The representative chromatograms of a urine sample fortified with the analytes (low 
QC) and subjected to the SPE pre-treatment is reported in Fig 4. 
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Fig. 3 
 
Chromatograms of a blank urine sample. Three MRM transitions are shown for the 
analytes and the ISs (quantification transition is reported first). 
87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 
 
Chromatograms of an urine sample fortified with the analytes and the ISs. 
Concentrations correspond to low QC. Three MRM transitions are shown for 
each analyte (quantification transition is reported first). 
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Method 
Validation 
 
Calibration curves were constructed by means of the least-square method and a 
1/x weighting factor was applied. Good linearity (r
2 
> 0.995) was obtained over the 
studied concentration ranges. The linearity range, slope, intercept and correlation 
coefficient for each analyte are summarized in Table. The LLOQ was 0.2 ng mL
-1 
for 
and 0.5 ng mL
-1
. Precision and accuracy at the LLOQ assessed in 6  fortified  
samples from different urine  sources  satisfied the 
acceptance criteria (i.e. RSD% ≤ 20% and deviation from the theoretical 
concentration within ± 20%). Extraction yield, precision and accuracy assays were 
carried out for each analyte at the low, medium, and high QC concentrations (6 
replicate each); mean results are provided in Table 3. Extraction yield values 
calculated herein are reflective of the combination of matrix effect and extraction 
recovery of the analytes. Results were satisfactory, being always higher than 80%. 
Precision and accuracy were also acceptable: RSD values were always lower than 
8.8% and accuracy ranged between 87.0% and 105.4%. 
 
 
- Selectivity 
 
The analysis of urine samples from 10 different healthy volunteers showed no 
evidence of unacceptable endogenous interference at the same MRM transitions 
and retention times of the analytes and the ISs, proving the selectivity of the method 
toward endogenous  compounds. 
 
 
- Stability 
 
Stability of the analytes was assessed in urine samples stored at room temperature 
for 24 h and after three freeze-thaw cycles. Stability was also evaluated in 
processed samples stored on the autosampler (+4°C) for 5 days and at -20°C for 7 
days. The mean observed concentrations of the analytes in the stored samples were 
always within ± 5% of the nominal concentrations, indicating that the analytes are 
stable under all tested conditions. 
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Table 2 
 
Linearity parameters. 
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Table  
 
Validation parameters: extraction yield, precision and accuracy data. 
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6.4. Conclusions 
 
 
 
 
An analytical method based on the use of liquid chromatography coupled with 
tandem mass spectrometry and on a solid phase extraction procedure for sample clean- 
up has been developed for the simultaneous determination of 22 glucocorticoids in 
human urine. Few other methods have been reported for the detection of some of 
the analytes [136,137], but to the best of knowledge this is the first one that includes 
all of them. 
The method has been validated according to the WADA criteria with 
satisfactory results and it will be used to investigate the glucocorticoids misuse in sports 
and discourage its use for doping. Acknowledgements 
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FOOTNOTES 
 
 
 
 
Some of the analytical methods developed during the Ph.D. program and presented 
herein, have been object of  scientific meeting communications: 
 
2013 
 
 Emanuele Morganti, Maria Assunta Santoro, Maria Addolorata Saracino,  
Roberto Mandrioli, Maria Augusta Raggi 
Fast MEKC Method for the Analysis of Adulterants Commonly Present in Street 
Drugs  
13° SAYCS (Sigma-Aldrich Young Chemists Simposium), Riccione, 27-30 
Ottobre 2013 (Abstract Book P22 ) 
 
 Emanuele Morganti, Laura Plizza, Roberto Mandrioli, Maria Augusta Raggi  
A Novel CE-Stacking Approach  for the Analysis of Ethinylestradiol and 
Dexamethasone Residues in Meat Samples 
13° SAYCS (Sigma-Aldrich Young Chemists Simposium), Riccione, 27-30 
Ottobre 2013 (Abstract Book P23 )  
 
 Francesca Bugamelli, Rosaria Trematore, Emanuele Morganti, Maria Augusta 
Raggi Determination of Phenylbutazone by means of HPLC with Amperometric 
Detector  
13° SAYCS (Sigma-Aldrich Young Chemists Simposium), Riccione, 27-30 
Ottobre 2013 (Abstract Book P5 ) 
 
 Vittorio Volterra, Maria Addolorata Saracino, Roberto Mandrioli, Francesca 
Bugamelli, Emanuele Morganti, Maria Augusta Raggi 
Uso di agomelatina in stati depressivi e monitoraggio terapeutico 
11° Congresso SIPB (Società Italiana di Psichiatria Biologica), Napoli, 19-21 
Settembre 2013 
(Abstract Book P.194) 
 
 Maria Addolorata Saracino, Emanuele Morganti, Roberto Mandrioli, Francesca 
Bugamelli, Nadia Ghedini, Maria Augusta Raggi  
An original method for the analysis of gamma-hydroxybutyric acid (GHB) in 
biological matrices 
22nd NMMC (National Meeting on Medicinal Chemistry), Roma, 10-13 
September 2013 
(Abstract Book P.AT.04) 
 
 Maria Addolorata Saracino, Chiara Marcheselli, Francesca Bugamelli, Emanuele 
Morganti, Maria Augusta Raggi 
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Club drugs: analysis of ketamine and norketamine in dried blood spots by HPLC-
DAD-MEPS 
24° International Symposium of Pharmaceutical and Biomedical Analysis - Recent 
Developments in Pharmaceutical Analysis  (PBA-RDPA 2013), Bologna, 30 June 
- 3 July 2013 (Abstract Book P 1-16) 
 
 
2012 
 
 Emanuele Morganti, Roberto Mandrioli, Maria Addolorata Saracino, Maria Chiara 
Pieri,  
Ernst Kenndler, Maria Augusta Raggi 
Determination of GHB by Means of Capillary Electrophoresis with Indirect UV 
Detection 
XII Giornata di Chimica dell’ Emilia Romagna, Ferrara, 17 Dicembre 2012  
(Abstract Book pag. 66) 
 
 Roberto Mandrioli, Emanuele Morganti, Migena Kasimi, Ernst Kenndler, Maria 
Chiara Pieri, Maria Augusta Raggi 
Un metodo originale per l’analisi di GHB in plasma umano mediante CE con 
rivelazione UV indiretta 
12° SAYCS (Sigma-Aldrich Young Chemists Simposium), Riccione, 1-3 Ottobre 
2012 (Abstract Book O 14) 
 
 Roberto Mandrioli, Emanuele Morganti, Maria Addolorata Saracino, Maria Chiara 
Pieri, Lorenzo Somaini, Maria Augusta Raggi 
Capillary electrophoresis with indirect UV detection for the Therapeutic Drug 
Monitoring (TDM) of GHB in human plasma 
21
st
 NMMC (National Meeting on Medicinal Chemistry), Palermo, 17-20 July 
2012  
(Abstract Book P33 pag. 121) 
 
 Stefano Manfredini, Silvia Vertuani, Gemma Malisardi, Marina Marini, 
Provvidenza Maria Abruzzo, Cosetta Marchionni, Maria Augusta Raggi, Francesca 
Bugamelli, Emanuele Morganti, Alessandra Modesti, Tania Gamberi, Carla 
Ferreri, Antonella Pini, Alessandro Ghezzo, Filippo Fortuna 
Tocotrienol supplementation: a novel approach to the complementary treatment of 
Friedreich’s Ataxia 
ChimAlSi 2012, IX Italian Congress of Food Chemistry. “Food,  Functional Foods 
and Nutraceuticals”, Ischia (NA), 3-7 June 2012 (Abstract Book P-116) 
  
 Maria Addolorata Saracino, Emanuele Morganti, Michele Protti, Maria Augusta 
Raggi 
Antioxidants as modulators in health and disease: an analytical point of view  
NPCF 6, 6° meeting Nuove Prospettive in Chimica Farmaceutica, Riccione (RN), 
15-17 Aprile 2012 (Abstract Book pag. 146) 
 
 
Other analytical methods resulted from the research performed during the three years of 
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the Ph.D. program has been object of publication: 
 
- I. Neri, C. Gurioli, M. A. Raggi, M.A. Saracino, E. Morganti, F Bugamelli, F. De Ponti, S. 
Vaccari, A. Patrizi, R. Balestri  
Detection of D-penicillamine in skin lesions in a case of dermal elastosis after a previous 
long-term treatment for Wilson's disease; 
Journal of the European Academy of Dermatology and Venereology, 29 (2015) 383-386 
 
- M. A. Saracino, C. Cannistraci, F. Bugamelli, E. Morganti, I. Neri, R. Balestri, A. Patrizi, 
M. A. Raggi 
A novel HPLC-electrochemical detection approach for the determination of D-
penicillamine in skin specimens; 
Talanta, 103 (2013) 355–360  
 
 
However, as it is not strictly related to the determination of psychoactive compounds, it 
has not been included in the present thesis work. 
 
Other manuscripts are in an advanced stage of preparation and will soon be sent to 
international journals. 
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